

# David Cunningham

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/75673/publications.pdf>

Version: 2024-02-01

787  
papers

83,451  
citations

910

119  
h-index

521

273  
g-index

799  
all docs

799  
docs citations

799  
times ranked

56558  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of thyroid disorders in adult and childhood Hodgkin lymphoma survivors 40 years after treatment. <i>Leukemia and Lymphoma</i> , 2022, 63, 562-572.	0.6	4
2	Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial. <i>International Journal of Hematology</i> , 2022, 115, 222-232.	0.7	15
3	Discordance between positron emission tomography standard uptake value and proliferation index in mantle cell lymphoma: An initial communication. <i>EJHaem</i> , 2022, 3, 249.	0.4	0
4	Treatment Response Assessment Maps (TRAMs), a new tool for CNS lymphoma. <i>EJHaem</i> , 2022, 3, 247-248.	0.4	1
5	Increasing frequency of gene copy number aberrations is associated with immunosuppression and predicts poor prognosis in gastric adenocarcinoma. <i>British Journal of Surgery</i> , 2022, 109, 291-297.	0.1	4
6	Optimising Multimodality Treatment of Resectable Oesophago-Gastric Adenocarcinoma. <i>Cancers</i> , 2022, 14, 586.	1.7	2
7	Which surgical strategy for colorectal cancer with synchronous hepatic metastases provides the best outcome? A comparison between primary first, liver first and simultaneous approach. <i>Updates in Surgery</i> , 2022, 74, 451-465.	0.9	7
8	Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study. <i>BJS Open</i> , 2022, 6, .	0.7	3
9	Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer. <i>Lancet, The</i> , 2022, 399, 905-907.	6.3	60
10	Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma – A comparison of the FLOT and MAGIC regimens. <i>European Journal of Cancer</i> , 2022, 163, 180-188.	1.3	8
11	Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors. <i>JCO Precision Oncology</i> , 2022, 6, e2100181.	1.5	33
12	Follicular dendritic cell sarcoma in the setting of Castleman disease. <i>British Journal of Haematology</i> , 2022, , .	1.2	1
13	Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study. <i>Current Oncology</i> , 2022, 29, 2174-2184.	0.9	0
14	Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 2048-2057.	0.8	65
15	Cost and clinical benefit of imaging surveillance after treatment for breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). <i>European Journal of Surgical Oncology</i> , 2022, 48, 748-751.	0.5	0
16	Author response to: Increasing frequency of gene copy number aberrations is associated with immunosuppression and predicts poor prognosis in gastric adenocarcinoma. <i>British Journal of Surgery</i> , 2022, , .	0.1	0
17	Abstract PR012: Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer. <i>Cancer Research</i> , 2022, 82, PR012-PR012.	0.4	0
18	Abstract A002: Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer. <i>Cancer Research</i> , 2022, 82, A002-A002.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Neoadjuvant chemotherapy improves survival in patients with oesophageal mucinous adenocarcinoma: Post-hoc analysis of the UK MRC OE02 and OE05 trials. <i>European Journal of Cancer</i> , 2022, 170, 140-148.	1.3	1
20	Can we predict the progression of premalignant pancreatic cystic tumors to ductal adenocarcinoma?. <i>Future Oncology</i> , 2022, 18, 2605-2612.	1.1	4
21	Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. <i>Blood</i> , 2022, 140, 2248-2260.	0.6	20
22	EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers. <i>Gut</i> , 2021, 70, 1632-1641.	6.1	24
23	Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours. <i>Gut</i> , 2021, 70, 1904-1913.	6.1	24
24	Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial. <i>British Journal of Haematology</i> , 2021, 192, 1015-1019.	1.2	8
25	FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome – final result of a UK National Cancer Research Institute prospective study. <i>British Journal of Haematology</i> , 2021, 192, 504-513.	1.2	27
26	Lymphomatoid papulosis mimicking relapsed angioimmunoblastic T-cell lymphoma on histology: the importance of clinicopathological correlation. <i>Histopathology</i> , 2021, 78, 470-473.	1.6	0
27	Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. <i>Blood</i> , 2021, 137, 637-645.	0.6	69
28	Adjuvant therapy following neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma in patients with clear resection margins. <i>Acta Oncologica</i> , 2021, 60, 672-680.	0.8	3
29	Clinical Performance of Abbreviated Liver MRI for the Follow-Up of Patients With Colorectal Liver Metastases. <i>American Journal of Roentgenology</i> , 2021, 216, 669-676.	1.0	8
30	<sup>18</sup> F-choline radiotracer positron emission tomography as a new means to monitor central nervous system lymphoma. <i>British Journal of Haematology</i> , 2021, 193, 1026-1026.	1.2	4
31	Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1). <i>Journal of Clinical Oncology</i> , 2021, 39, 990-1000.	0.8	30
32	Relapsed/Refractory International Prognostic Index (R-IPPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2021, 96, 599-605.	2.0	8
33	<sup>227</sup> Th-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I Study. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 672-681.	0.7	14
34	Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer. <i>Nature Ecology and Evolution</i> , 2021, 5, 1024-1032.	3.4	16
35	Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL): Quantifying the direct economic costs of post-treatment radiological surveillance. <i>Journal of Clinical Oncology</i> , 2021, 39, e19574-e19574.	0.8	0
36	Fibrin-associated diffuse large B-cell lymphoma misdiagnosed as breast implant-associated anaplastic large B-cell lymphoma. <i>Histopathology</i> , 2021, 79, 269-271.	1.6	8

#	ARTICLE	IF	CITATIONS
37	Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity.. Journal of Clinical Oncology, 2021, 39, 7518-7518.	0.8	11
38	Coastal: A phase 3 study of the PI3KÎ inhibitor zandelisib with rituximab (R) versus immunochemotherapy in patients with relapsed indolent non-Hodgkinâ€™s lymphoma (iNHL).. Journal of Clinical Oncology, 2021, 39, TPS7573-TPS7573.	0.8	2
39	Maintenance durvalumab after first-line platinum-based chemotherapy in advanced oesophago-gastric (OG) adenocarcinoma: Results from the PLATFORM trial.. Journal of Clinical Oncology, 2021, 39, 4015-4015.	0.8	6
40	Digital histological markers based on routine H&E slides to predict benefit from maintenance immunotherapy in esophagogastric adenocarcinoma.. Journal of Clinical Oncology, 2021, 39, e16074-e16074.	0.8	1
41	Pulmonary manifestations of grade III lymphomatoid granulomatosis complicated by haemophagocytic lymphohistiocytosis: Rare disorders. EJHaem, 2021, 2, 669-670.	0.4	0
42	Are treatment response assessment maps (TRAMs) and 18 Fâ€choline positron emission tomography the future of central nervous system lymphoma imaging?. British Journal of Haematology, 2021, 195, e116-e119.	1.2	2
43	Chemotherapy with nivolumab in advanced gastro-oesophageal adenocarcinoma. Lancet, The, 2021, 398, 2-3.	6.3	2
44	Chronic lymphocytic leukaemia and Richter's transformation: multimodal review and new imaging paradigms. Clinical Radiology, 2021, 76, 789-800.	0.5	3
45	O17-1 Subcutaneous (SC) epcoritamab induces complete responses across R/R B-cell NHL subtypes: Updated dose-escalation data. Annals of Oncology, 2021, 32, S292.	0.6	0
46	A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies. Leukemia and Lymphoma, 2021, 62, 2625-2636.	0.6	3
47	A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAFV600 wild-type colorectal cancer. Cellular Oncology (Dordrecht), 2021, 44, 1197-1206.	2.1	2
48	The role of surgery after prolonged primary chemotherapy for advanced oesophageal adenocarcinoma. Journal of Surgical Oncology, 2021, 124, 1296-1305.	0.8	0
49	Clinical utility of clonal origin determination in managing recurrent hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1159-1167.	1.4	6
50	ABCL-454: CheckMate 436: Extended Follow-Up from the Phase 2 Study Investigating Nivolumab Plus Brentuximab Vedotin (BV) for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (R/R) Tj ETQq0 0 0 rgeT /Overlock 10 Tf 5		
51	Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet, The, 2021, 398, 1157-1169.	6.3	159
52	Development and validation of deep learning classifiers to detect Epstein-Barr virus and microsatellite instability status in gastric cancer: a retrospective multicentre cohort study. The Lancet Digital Health, 2021, 3, e654-e664.	5.9	69
53	Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction. European Journal of Cancer, 2021, 157, 278-290.	1.3	8
54	Minimal residual disease (MRD) detection with circulating tumor DNA (ctDNA) from personalized assays in stage II-III colorectal cancer patients in a U.K. multicenter prospective study (TRACC).. Journal of Clinical Oncology, 2021, 39, 102-102.	0.8	20

#	ARTICLE	IF	CITATIONS
55	Perioperative FLOT plus anti-PD-L1 avelumab (FLOT-A) in resectable oesophagogastric adenocarcinoma (OGA): Interim safety analysis results from the ICONIC trial.. Journal of Clinical Oncology, 2021, 39, 201-201.	0.8	8
56	The Mutational Concordance of Fixed Formalin Paraffin Embedded and Fresh Frozen Gastro-Oesophageal Tumours Using Whole Exome Sequencing. Journal of Clinical Medicine, 2021, 10, 215.	1.0	5
57	Can pre-transplant 18F-choline positron emission tomography predict relapse following autologous stem cell transplantation in primary central nervous system lymphoma?. Bone Marrow Transplantation, 2021, , .	1.3	0
58	A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma. HemaSphere, 2021, 5, e656.	1.2	6
59	Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. Nature Cancer, 2021, 2, 1321-1337.	5.7	66
60	Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nature Cancer, 2021, 2, 1305-1320.	5.7	123
61	Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Cost Evaluation Study of Management and Surveillance, and Review of the Recent USA and UK Guidelines. Blood, 2021, 138, 4014-4014.	0.6	0
62	hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. Cancers, 2021, 13, 5758.	1.7	5
63	Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Nature Communications, 2021, 12, 6738.	5.8	10
64	Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-203). Blood, 2021, 138, 813-813.	0.6	7
65	Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleuce (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7). Blood, 2021, 138, 430-430.	0.6	9
66	Bile Acid Malabsorption as a Consequence of Cancer Treatment: Prevalence and Management in the National Leading Centre. Cancers, 2021, 13, 6213.	1.7	5
67	DCE-MRI is more sensitive than IVIM-DWI for assessing anti-angiogenic treatment-induced changes in colorectal liver metastases. Cancer Imaging, 2021, 21, 67.	1.2	4
68	Randomized, open-label, phase 2 study of andeciximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival. , 2021, 9, e003580.		20
69	Analysis of <i>KRAS</i> , <i>NRAS</i> , <i>BRAF</i> , <i>PIK3CA</i> and <i>TP53</i> mutations in a large prospective series of locally advanced rectal cancer patients. International Journal of Cancer, 2020, 146, 94-102.	2.3	34
70	Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ Cells. Hepatology, 2020, 72, 982-996.	3.6	30
71	MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer. Clinical Cancer Research, 2020, 26, 183-192.	3.2	79
72	R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial. Annals of Hematology, 2020, 99, 105-112.	0.8	6

#	ARTICLE	IF	CITATIONS
73	Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer. <i>Pancreas</i> , 2020, 49, 62-75.	0.5	22
74	Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial Data. <i>Frontiers in Oncology</i> , 2020, 10, 1634.	1.3	2
75	Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial. <i>JCO Precision Oncology</i> , 2020, 4, 1152-1162.	1.5	6
76	Early interval and serial positron emission tomographyâ€computed tomography (PETâ€CT) after an indeterminate response defined by a PET scored 4 on the Deauville scale in lymphoma. <i>British Journal of Haematology</i> , 2020, 190, e357-e362.	1.2	0
77	Deep learning as a staging tool in gastric cancer. <i>Annals of Oncology</i> , 2020, 31, 827-828.	0.6	6
78	Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02,) Tj ETQq0 0 0 rgB/Overlozh 10 Tf 50	0.1	0
79	Comparison of a coaxial versus non-coaxial liver biopsy technique in an oncological setting: diagnostic yield, complications and seeding risk. <i>European Radiology</i> , 2020, 30, 6702-6708.	2.3	14
80	Transition from open and laparoscopic to robotic pancreaticoduodenectomy in a UK tertiary referral hepatobiliary and pancreatic centre - Early experience of robotic pancreaticoduodenectomy. <i>Hpb</i> , 2020, 22, 1637-1644.	0.1	15
81	International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. <i>Blood</i> , 2020, 135, 2041-2048.	0.6	158
82	International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. <i>Journal of Clinical Oncology</i> , 2020, 38, 2510-2518.	0.8	92
83	Focal splenic lesions in indolent Bâ€NHL: association with high grade transformation and safe percutaneous biopsy. <i>British Journal of Haematology</i> , 2020, 189, e157-e160.	1.2	2
84	Histological intratumoral heterogeneity in pretreatment esophageal cancer biopsies predicts survival benefit from neoadjuvant chemotherapy: results from the UK MRC OE02 trial. <i>Ecological Management and Restoration</i> , 2020, 33, .	0.2	1
85	O-9 Discordant prognostic significance of negative lymph node size in patients with oesophageal cancer treated with either surgery or neoadjuvant chemotherapy and surgery: Results from the MRC OE02 trial. <i>Annals of Oncology</i> , 2020, 31, 234-235.	0.6	0
86	Financial burden and financial toxicity in patients with colorectal, gastro-oesophageal, and pancreaticobiliary cancers: A UK study. <i>Journal of Cancer Policy</i> , 2020, 25, 100236.	0.6	3
87	Inactivation of <i>NF1</i> Promotes Resistance to EGFR Inhibition in <i>KRAS/NRAS/BRAFV600</i> -Wild-Type Colorectal Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 835-846.	1.5	22
88	Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 398-411.	5.1	152
89	Imaging and clinical correlates with regorafenib in metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , 2020, 86, 102020.	3.4	9
90	Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study. <i>ESMO Open</i> , 2020, 5, e000638.	2.0	47

#	ARTICLE	IF	CITATIONS
91	On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 468-478.	1.9	29
92	Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. <i>Journal of Hepatology</i> , 2020, 73, 1109-1117.	1.8	25
93	Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203). <i>Blood</i> , 2020, 136, 36-37.	0.6	6
94	ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma: Five year follow-up.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4516-4516.	0.8	20
95	Comparison of efficacy and safety with obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: Updated results from the phase III Gallium Study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8023-8023.	0.8	9
96	TRACC: Tracking mutations in cell-free DNA to predict relapse in early colorectal cancer—A randomized study of circulating tumour DNA (ctDNA) guided adjuvant chemotherapy versus standard of care chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS4120-TPS4120.	0.8	8
97	Identification of cancer hallmarks associated with benefit in advanced gastroesophageal adenocarcinoma patients treated with checkpoint blockade.. <i>Journal of Clinical Oncology</i> , 2020, 38, 439-439.	0.8	7
98	Abstract 5720: MicroRNA deregulation of the serine synthesis pathway controls intrinsic and non-cell autonomous mechanism of resistance to Regorafenib in metastatic colorectal cancer (mCRC). , 2020, , .		0
99	Evaluating maintenance therapies in advanced oesophago-gastric adenocarcinoma (OGA): Interim analysis and biomarker results from the PLATFORM study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 282-282.	0.8	1
100	SOlar: A translational phase II study of single-agent olaparib in the treatment of advanced esophagogastric cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS471-TPS471.	0.8	0
101	P-138 A comparison of the transcriptomic profiles of matched tissue from primary colorectal cancer and corresponding secondary lung metastases. <i>Annals of Oncology</i> , 2020, 31, S134-S135.	0.6	1
102	The Value of Follow-up Following Complete Remission with Frontline Chemotherapy for DLBCL. <i>Blood</i> , 2020, 136, 31-32.	0.6	0
103	Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies. <i>Frontiers in Oncology</i> , 2019, 9, 618.	1.3	9
104	Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 3081-3089.	0.8	120
105	ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK. <i>Clinical Colorectal Cancer</i> , 2019, 18, 280-291.e5.	1.0	16
106	Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. <i>Cancer Cell</i> , 2019, 36, 35-50.e9.	7.7	179
107	Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in <i>KRAS</i> -Mutant Cancers. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1396-1404.	1.9	14
108	Panitumumab Alone for Maintenance Treatment in Advanced Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 1262.	3.4	3

#	ARTICLE	IF	CITATIONS
109	The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy. <i>European Journal of Cancer</i> , 2019, 117, 84-90.	1.3	21
110	Outcomes of Patients with Early Onset Colorectal Cancer Treated in a UK Specialist Cancer Center. <i>Cancers</i> , 2019, 11, 1558.	1.7	25
111	Clonal diversity of MYC amplification evaluated by fluorescent in situ hybridisation and digital droplet polymerase chain reaction in oesophagogastric cancer: Results from a prospective clinical trial screening programme. <i>European Journal of Cancer</i> , 2019, 122, 12-21.	1.3	2
112	Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-17.	0.7	8
113	Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeneity and convergent evolution. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 143, 153-163.	2.0	49
114	Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma. <i>JAMA Surgery</i> , 2019, 154, 1038.	2.2	154
115	Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: A pooled analysis of four randomised trials. <i>European Journal of Cancer</i> , 2019, 121, 40-47.	1.3	43
116	Comparison of Outcomes Between Patients with MYC Rearranged DLBCL and Double/Triple Hit High-Grade B-Cell Lymphoma: A Pan-London Retrospective Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S248.	0.2	0
117	Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 3392-3400.	0.8	293
118	Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma. <i>JAMA Oncology</i> , 2019, 5, 1181.	3.4	12
119	Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma. <i>Cancers</i> , 2019, 11, 736.	1.7	15
120	Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes. <i>Scientific Reports</i> , 2019, 9, 7665.	1.6	36
121	International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis. <i>Gut</i> , 2019, 68, 1624-1632.	6.1	173
122	Exploratory Analysis of Plasma Neurotensin as a Novel Biomarker for Early Detection of Colorectal Polyp and Cancer. <i>Hormones and Cancer</i> , 2019, 10, 128-135.	4.9	13
123	Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. <i>Lancet Oncology</i> , 2019, 20, 663-673.	5.1	773
124	Primary Tumor Resection in Patients with Incurable Localized or Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis. <i>World Journal of Surgery</i> , 2019, 43, 1829-1840.	0.8	33
125	Florid T follicular helper cell hyperplasia associated with extranodal marginal zone lymphoma: a diagnostic pitfall which may mimic T cell lymphoma. <i>Histopathology</i> , 2019, 75, 287-290.	1.6	5
126	miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3830-3838.	3.2	42



#	ARTICLE	IF	CITATIONS
127	A Golden Conundrum. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 631-632.	2.5	0
128	Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review. Current Problems in Cancer, 2019, 43, 487-494.	1.0	9
129	Contemporary Tailored Oncology Treatment of Biliary Tract Cancers. Gastroenterology Research and Practice, 2019, 2019, 1-15.	0.7	5
130	Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment. , 2019, 7, 309.		112
131	DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial. European Journal of Cancer, 2019, 123, 48-57.	1.3	5
132	Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer. Oncogene, 2019, 38, 1717-1733.	2.6	29
133	A Multicenter Phase II Study of AMG 337 in Patients with <i>MET</i> -Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other <i>MET</i> -Amplified Solid Tumors. Clinical Cancer Research, 2019, 25, 2414-2423.	3.2	54
134	Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience. Clinical Colorectal Cancer, 2019, 18, 64-71.e1.	1.0	10
135	Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC). Blood, 2019, 134, 400-400.	0.6	2
136	ME-401-003 (TIDAL): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 Investigating Continuous and Intermittent Dosing Schedules in Patients with Relapsed/Refractory Follicular Lymphoma. Blood, 2019, 134, 5244-5244.	0.6	4
137	Impact of age and sex on chemotherapy (CTx) efficacy, toxicity and survival in early oesophagogastric (OG) cancer: A pooled analysis of 3265 patients from four large randomised trials (OE02, OE05, MAGIC) <a href="#">Tj ETQq1 b&amp;784314 rgBT /Ov</a>		
138	Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R2-CHOP in subjects with previously untreated, high-risk DLBCL. Journal of Clinical Oncology, 2019, 37, 7520-7520.	0.8	7
139	Comparison of clinical scoring systems in aggressive B-cell lymphomas (BCL): An individual patient-level analysis across international trials (SEAL). Journal of Clinical Oncology, 2019, 37, 7544-7544.	0.8	3
140	A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1). Journal of Clinical Oncology, 2019, 37, 4-4.	0.8	24
141	DNA methylation signature predictive of benefit from neoadjuvant chemotherapy in esophageal adenocarcinoma: Results from the MRC OE02 phase III trial. Journal of Clinical Oncology, 2019, 37, 43-43.	0.8	1
142	MSI-GC-01: Individual patient data (IPD) meta-analysis of microsatellite instability (MSI) and gastric cancer (GC) from four randomized clinical trials (RCTs). Journal of Clinical Oncology, 2019, 37, 66-66.	0.8	17
143	Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instability-high (MSI-H) tumors. Journal of Clinical Oncology, 2019, 37, 670-670.	0.8	24
144	A phase II, open-label, randomized study to evaluate the efficacy and safety of andecaliximab combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma. Journal of Clinical Oncology, 2019, 37, 75-75.	0.8	6

#	ARTICLE	IF	CITATIONS
145	3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. Health Technology Assessment, 2019, 23, 1-88.	1.3	20
146	Evaluation of intratumoral T cells in biopsies from advanced gastric cancer patients treated with andecaliximab and nivolumab.. Journal of Clinical Oncology, 2019, 37, 118-118.	0.8	0
147	Exploratory evaluation of baseline tumor biomarkers and their association with response and survival in patients with previously treated advanced gastric cancer treated with andecaliximab combined with nivolumab versus nivolumab.. Journal of Clinical Oncology, 2019, 37, 148-148.	0.8	1
148	CEA expression patterns determine response and resistance to the CEA-TCB bispecific immunotherapy antibody in colorectal cancer patient derived organoids.. Journal of Clinical Oncology, 2019, 37, 535-535.	0.8	1
149	Abstract 2646: Proteomic approaches to study cetuximab resistance in <i>RAS/BRAF</i> wild type colorectal cancer. , 2019, , .		0
150	Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science, 2018, 359, 920-926.	6.0	1,199
151	Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy – results from the MRC OE02 oesophageal cancer trial. Histopathology, 2018, 72, 1180-1188.	1.6	31
152	CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. Lancet Haematology, the, 2018, 5, e190-e200.	2.2	50
153	KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. Scientific Reports, 2018, 8, 1445.	1.6	55
154	Chemotherapy for Advanced Pancreatic Cancer. , 2018, , 875-921.		0
155	Adjuvant Chemotherapy in Pancreatic Cancer. , 2018, , 1039-1071.		0
156	3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncology, The, 2018, 19, 562-578.	5.1	133
157	Emergency Presentation of Esophagogastric Cancer. Annals of Surgery, 2018, 267, 711-715.	2.1	17
158	Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study. Clinical Colorectal Cancer, 2018, 17, e69-e76.	1.0	44
159	Adjuvant Chemotherapy Following Neoadjuvant Chemotherapy Plus Surgery for Patients With Gastroesophageal Cancer – Is There Room for Improvement?. JAMA Oncology, 2018, 4, 38.	3.4	3
160	Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer. Gut, 2018, 67, 1780-1792.	6.1	19
161	Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. New England Journal of Medicine, 2018, 378, 331-344.	13.9	564
162	Circulating tumour DNA, a promising biomarker for the management of colorectal cancer. Critical Reviews in Oncology/Hematology, 2018, 122, 72-82.	2.0	40

#	ARTICLE	IF	CITATIONS
163	MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. <i>Gastroenterology</i> , 2018, 154, 1066-1079.e5.	0.6	94
164	Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital. <i>Leukemia and Lymphoma</i> , 2018, 59, 1586-1595.	0.6	10
165	Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. <i>Gut</i> , 2018, 67, 1484-1492.	6.1	59
166	Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patientâ€“Level Analysis of Multiple Randomized Trials (SEAL). <i>Journal of Clinical Oncology</i> , 2018, 36, 2593-2602.	0.8	59
167	Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial. <i>European Journal of Cancer</i> , 2018, 105, 71-78.	1.3	24
168	SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. <i>British Journal of Cancer</i> , 2018, 119, 1332-1338.	2.9	19
169	Immunotherapy and pancreatic cancer: unique challenges and potential opportunities. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591881628.	1.4	56
170	Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre. <i>Anticancer Research</i> , 2018, 38, 5943-5949.	0.5	2
171	Identifying the role of neutrophil-to-lymphocyte ratio and platelets-to-lymphocyte ratio as prognostic markers in patients undergoing resection of pancreatic ductal adenocarcinoma. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , 2018, 22, 197.	0.1	20
172	Neoadjuvant rectal score: run with the hare and hunt with the hounds. <i>Annals of Oncology</i> , 2018, 29, 2261-2262.	0.6	9
173	Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing. <i>Clinical Chemistry</i> , 2018, 64, 1626-1635.	1.5	46
174	Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. <i>Cancer Discovery</i> , 2018, 8, 1270-1285.	7.7	187
175	Assessment of a Noninvasive Exhaled Breath Test for the Diagnosis of Oesophagogastric Cancer. <i>JAMA Oncology</i> , 2018, 4, 970.	3.4	82
176	Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 280-284.	1.0	33
177	Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients. <i>Clinical Colorectal Cancer</i> , 2018, 17, 223-230.	1.0	27
178	Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial. <i>British Journal of Cancer</i> , 2018, 119, 27-35.	2.9	19
179	Is organ preservation in rectal cancer ready for prime time?. <i>Lancet, The</i> , 2018, 391, 2480-2482.	6.3	6
180	The evolving immunotherapeutic landscape in advanced oesophagogastric cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591878622.	1.4	5

#	ARTICLE	IF	CITATIONS
181	Rapid access clinic for unexplained lymphadenopathy and suspected malignancy: prospective analysis of 1000 patients. <i>BMC Hematology</i> , 2018, 18, 19.	2.6	6
182	Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Preliminary Results from the Phase 2 CheckMate 436 Trial. <i>Blood</i> , 2018, 132, 1691-1691.	0.6	4
183	Obinutuzumab-Based Immunochemotherapy Prolongs Progression-Free Survival and Time to Next Anti-Lymphoma Treatment in Patients with Previously Untreated Follicular Lymphoma: Four-Year Results from the Phase III GALLIUM Study. <i>Blood</i> , 2018, 132, 1597-1597.	0.6	13
184	Safety and clinical activity of durvalumab monotherapy in patients with gastroesophageal cancers.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4032-4032.	0.8	4
185	Iconic: Peri-operative immuno-chemotherapy in operable oesophageal and gastric cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4139-TPS4139.	0.8	4
186	Percutaneous radiofrequency versus microwave ablation for the treatment of colorectal liver metastases.. <i>Journal of Clinical Oncology</i> , 2018, 36, 401-401.	0.8	3
187	Molecular subtype assay to reveal anti-EGFR response sub-clones in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 658-658.	0.8	7
188	Genomic loss of heterozygosity and survival in the REAL3 trial. <i>Oncotarget</i> , 2018, 9, 36654-36665.	0.8	13
189	PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer. <i>Health Technology Assessment</i> , 2018, 22, 1-114.	1.3	82
190	Subgroup analysis by measurable metastatic lesion (ML) number and selected lesion locations (LL) at baseline (BL) in NAPOLI-1: A phase III study of liposomal irinotecan (nal-IRI)±5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 460-460.	0.8	0
191	Subgroup analysis by baseline pain intensity (BPI) and analgesic use (BAU) in NAPOLI-1: A phase III study of liposomal irinotecan (nal IRI)±5-fluorouracil/ leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 379-379.	0.8	0
192	Single nucleotide polymorphisms of mir-608, LCS-6, and overall survival in the MAGIC trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 58-58.	0.8	0
193	Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal-IRI)±5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based (gem) therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 410-410.	0.8	1
194	Complications and seeding risk after percutaneous liver biopsy in an oncological setting.. <i>Journal of Clinical Oncology</i> , 2018, 36, 246-246.	0.8	1
195	Surgical quality and the impact of liver resection on outcome in the New EPOC study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3559-3559.	0.8	0
196	Abstract 4977: MIR1307 mediates pancreatic cancer resistance to FOLFIRINOX chemotherapy by affecting response to DNA damage. , 2018, , .		0
197	Abstract 4339: Molecular subtypes and novel genetic mechanisms of primary and acquired anti-EGFR resistance in colorectal cancer in the Prospect C biomarker trial. , 2018, , .		1
198	The results of local excision with or without postoperative adjuvant chemoradiotherapy for early rectal cancer among patients choosing to avoid radical surgery. <i>Colorectal Disease</i> , 2017, 19, 139-147.	0.7	20

#	ARTICLE	IF	CITATIONS
199	Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet</i> , The, 2017, 389, 1011-1024.	6.3	1,475
200	Molecular Stratification of Colorectal Cancer: Moving from the Laboratory to Clinical Practice. <i>Current Colorectal Cancer Reports</i> , 2017, 13, 81-90.	1.0	0
201	Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients. <i>Oncologist</i> , 2017, 22, 402-408.	1.9	31
202	Mismatch Repair Deficiency, Microsatellite Instability, and Survival. <i>JAMA Oncology</i> , 2017, 3, 1197.	3.4	398
203	Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 486-499.	5.1	60
204	Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2â€“3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 357-370.	5.1	244
205	Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 347-356.	5.1	132
206	Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/â€“ cetuximab in oesophageal cancer. <i>British Journal of Cancer</i> , 2017, 116, 709-716.	2.9	58
207	Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma â€“ Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e244.	5.1	1
208	Multiplexed single cell protein expression analysis in solid tumours using a miniaturised microfluidic assay. <i>Convergent Science Physical Oncology</i> , 2017, 3, 024003.	2.6	13
209	Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy. <i>Oncologist</i> , 2017, 22, 728-736.	1.9	10
210	Oesophageal cancer. <i>Lancet</i> , The, 2017, 390, 2383-2396.	6.3	796
211	Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 565-575.	3.7	362
212	Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma. <i>JAMA Oncology</i> , 2017, 3, 620.	3.4	233
213	Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003â€“2013. <i>Leukemia and Lymphoma</i> , 2017, 58, 1805-1813.	0.6	13
214	Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1467-1482.	5.1	265
215	Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy. <i>Clinical Cancer Research</i> , 2017, 23, 7543-7549.	3.2	12
216	Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial. <i>Annals of Oncology</i> , 2017, 28, 2511-2516.	0.6	64

#	ARTICLE	IF	CITATIONS
217	Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer. <i>British Journal of Cancer</i> , 2017, 117, 1478-1485.	2.9	118
218	Allogeneic Hematopoietic Cell Transplantation Outcomes After Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma (CA209-039 and CheckMate 205). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S326-S327.	0.2	2
219	Oesophageal cancer. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17048.	18.1	671
220	Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1249-1260.	5.1	187
221	Diagnostic accuracy of high-resolution MRI as a method to predict potentially safe endoscopic and surgical planes in patients with early rectal cancer. <i>BMJ Open Gastroenterology</i> , 2017, 4, e000151.	1.1	27
222	Beyond genomics – Targeting the epigenome in diffuse large B-cell lymphoma. <i>Cancer Treatment Reviews</i> , 2017, 59, 132-137.	3.4	5
223	In Reply. <i>Oncologist</i> , 2017, 22, 1411-1412.	1.9	0
224	The Role of Systemic Therapy in Resectable Gastric and Gastro-oesophageal Junction Cancer. <i>Current Treatment Options in Oncology</i> , 2017, 18, 69.	1.3	11
225	Neoadjuvant chemotherapy in oesophageal adenocarcinoma – Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e641.	5.1	1
226	Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials. <i>BMC Cancer</i> , 2017, 17, 262.	1.1	16
227	Attitudes of Patients With Gastrointestinal Cancers Toward Research Biopsies. <i>Clinical Colorectal Cancer</i> , 2017, 16, e181-e189.	1.0	6
228	Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 42-49.	0.4	31
229	The selection process can improve the outcome in locally advanced and recurrent colorectal cancer: activity and results of a dedicated multidisciplinary colorectal cancer centre. <i>Colorectal Disease</i> , 2017, 19, 331-338.	0.7	22
230	Dalotuzumab in chemorefractory <i>KRAS</i> exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial. <i>International Journal of Cancer</i> , 2017, 140, 431-439.	2.3	4
231	Heterogeneity of MYC amplification in oesophagogastric (OG) carcinoma: Results from a prospective screening study. <i>Annals of Oncology</i> , 2017, 28, iii2-iii3.	0.6	0
232	Diagnostic accuracy and safety of coaxial core-needle biopsy (CNB) system in a predominanty gastrointestinal oncology patient population, treated at the Royal Marsden (RM) Hospital. <i>Annals of Oncology</i> , 2017, 28, iii6.	0.6	2
233	A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 394.	0.7	72
234	Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4006-4006.	0.8	142

#	ARTICLE	IF	CITATIONS
235	Biomarker prediction of efficacy to vandetanib plus gemcitabine in a phase II double blind multicenter randomized placebo-controlled trial in locally advanced or metastatic pancreatic carcinoma.. Journal of Clinical Oncology, 2017, 35, 4104-4104.	0.8	1
236	Updated safety and clinical activity of durvalumab monotherapy in previously treated patients with stage IIIB/IV NSCLC.. Journal of Clinical Oncology, 2017, 35, 9085-9085.	0.8	7
237	The prognostic value of baseline neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for predicting clinical outcome in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398) + 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV.. Journal of Clinical Oncology, 2017, 35, e15795-e15795.	0.8	1
238	Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment. Oncotarget, 2017, 8, 64999-65008.	0.8	14
239	Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer. World Journal of Gastrointestinal Oncology, 2017, 9, 333.	0.8	7
240	Chemotherapy for Advanced Pancreatic Cancer. , 2017, , 1-48.		0
241	iMYC: Proof-of-concept study of ibrutinib in c-MYC and HER2 amplified oesophagogastric carcinoma.. Journal of Clinical Oncology, 2017, 35, TPS221-TPS221.	0.8	1
242	Characteristics of long-term survivors in a randomized phase III trial (NAPOLI-1) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI); Tj ETQq0 0 0 rg018 Overlook 10 Tf 50		
243	Systemic chemotherapy (CT) as salvage treatment for locally advanced rectal cancer (LARC) patients (pts) who fail to respond to neoadjuvant chemoradiotherapy (CRT).. Journal of Clinical Oncology, 2017, 35, 709-709.	0.8	49
244	A novel phase I/IIa open-label study of IMM-101 in combination with selected standard of care regimens in patients with metastatic cancer or unresectable cancer at study entry.. Journal of Clinical Oncology, 2017, 35, e14627-e14627.	0.8	0
245	Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-oesophageal junction adenocarcinoma. OncoTargets and Therapy, 2016, Volume 9, 4539-4548.	1.0	3
246	An Association of Cancer Physiciansâ€™ strategy for improving services and outcomes for cancer patients. Ecanermedscience, 2016, 10, 608.	0.6	5
247	miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial. Oncotarget, 2016, 7, 12672-12681.	0.8	34
248	MicroRNAs as biomarkers of resistance to HER2 inhibitors in combination with chemotherapy in gastro-oesophageal cancer cell lines. Annals of Oncology, 2016, 27, vi549.	0.6	1
249	The Association of Cancer Physicians responds to â€œCancer drugs, survival, and ethicsâ€• BMJ, The, 2016, 355, i6487.	3.0	3
250	Chemotherapy for Advanced Pancreatic Cancer. , 2016, , 1-48.		0
251	PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer. Annals of Oncology, 2016, 27, 1557-1565.	0.6	64
252	High-Level Clonal <i>FGFR</i> Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. Cancer Discovery, 2016, 6, 838-851.	7.7	222

#	ARTICLE	IF	CITATIONS
253	Encouraging results for PD-1 inhibition in gastric cancer. <i>Lancet Oncology</i> , The, 2016, 17, 682-683.	5.1	14
254	Quality of life, long-term survivors and long-term outcome from the ABC-02 study. <i>British Journal of Cancer</i> , 2016, 114, 965-971.	2.9	39
255	Efficacy and toxicity of salvage weekly paclitaxel chemotherapy in non-Asian patients with advanced oesophagogastric adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 104-112.	1.4	6
256	Esophagogastric Adenocarcinoma: Is More Chemotherapy Better?. <i>Current Treatment Options in Oncology</i> , 2016, 17, 21.	1.3	5
257	Supportive housing and surveillance. <i>International Journal of Drug Policy</i> , 2016, 34, 72-79.	1.6	34
258	Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2016, 27, v38-v49.	0.6	1,212
259	Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (Râ€‹<sc>CHOP</sc>) in the management of primary mediastinal Bâ€‹cell lymphoma: a subgroup analysis of the <sc>UK NCRI</sc> Râ€‹<sc>CHOP</sc> 14 versus 21 trial. <i>British Journal of Haematology</i> , 2016, 175, 668-672.	1.2	38
260	Targeting deficient DNA damage repair in gastric cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1757-1766.	0.9	16
261	Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study. <i>British Journal of Cancer</i> , 2016, 115, 420-424.	2.9	9
262	Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. <i>Carcinogenesis</i> , 2016, 37, 852-857.	1.3	15
263	Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. <i>Nature Medicine</i> , 2016, 22, 1294-1302.	15.2	342
264	Quality of life during first-line FOLFOX4Â±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial. <i>ESMO Open</i> , 2016, 1, e000041.	2.0	15
265	Survival Outcomes in Asymptomatic Patients With Normal Conventional Imaging but Raised Carcinoembryonic Antigen Levels in Colorectal Cancer Following Positron Emission Tomography-Computed Tomography Imaging. <i>Oncologist</i> , 2016, 21, 1502-1508.	1.9	16
266	Genomic loss of heterozygosity (LOH) and survival in patients (pts) treated with epirubicin, oxaliplatin, capecitabine (EOC) Â± panitumumab (P) in the REAL3 trial. <i>Annals of Oncology</i> , 2016, 27, vi220.	0.6	3
267	Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2721-2727.	0.8	214
268	Patientsâ€™ willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey. <i>Trials</i> , 2016, 17, 17.	0.7	148
269	Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective study. <i>BMC Cancer</i> , 2016, 16, 112.	1.1	17
270	Exclusion of Gastrointestinal Cancer Patients With Prior Cancer From Clinical Trials: Is This Justified?. <i>Clinical Colorectal Cancer</i> , 2016, 15, e53-e59.	1.0	27



#	ARTICLE	IF	CITATIONS
271	Response. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv405.	3.0	1
272	Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial. <i>Annals of Oncology</i> , 2016, 27, 687-692.	0.6	82
273	Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. <i>Lancet Haematology</i> , 2016, 3, e196-e204.	2.2	344
274	AREG and EREG as Predictive Biomarkers for Wild-Type Colorectal Cancer Treated With Panitumumab. <i>JAMA Oncology</i> , 2016, 2, 578.	3.4	8
275	Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. <i>Targeted Oncology</i> , 2016, 11, 383-400.	1.7	40
276	Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. <i>Annals of Oncology</i> , 2016, 27, 673-679.	0.6	62
277	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. <i>Lancet</i> , 2016, 387, 545-557.	6.3	878
278	International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. <i>Pancreatology</i> , 2016, 16, 14-27.	0.5	81
279	Improved survival in resected oesophageal and gastric adenocarcinomas over a decade: the Royal Marsden experience 2001-2010. <i>Gastric Cancer</i> , 2016, 19, 1114-1124.	2.7	8
280	Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. <i>Annals of Oncology</i> , 2016, 27, 134-140.	0.6	88
281	Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies. <i>Clinical Pharmacokinetics</i> , 2016, 55, 397-405.	1.6	72
282	The Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma As Determined By Whole Genome Expression Profiling on Paraffin Embedded Tissue Is Independently Associated with Reduced Overall and Progression Free Survival in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Phase III Trial. <i>Blood</i> , 2016, 128, 1746-1746.	0.6	9
283	Utility of Progression-Free Survival at 24 Months (PFS24) to Predict Subsequent Outcome for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials: Findings from a Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 5853 Patients. <i>Blood</i> , 2016, 128, 3027-3027.	0.6	5
284	Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients. <i>Blood</i> , 2016, 128, 4196-4196.	0.6	1
285	PET-PANC: Multi-centre prospective diagnostic accuracy and clinical value trial of FDG PET/CT in the diagnosis and management of suspected pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 4008-4008.	0.8	12
286	TACE 2: A randomized placebo-controlled, double-blinded, phase III trial evaluating sorafenib in combination with transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma (HCC) Background. <i>Journal of Clinical Oncology</i> , 2016, 34, 4018-4018.	0.8	8
287	Randomized phase 2 study of paclitaxel (PTX), trastuzumab (T) with or without MM-111 in HER2 expressing gastroesophageal cancers (GEC). <i>Journal of Clinical Oncology</i> , 2016, 34, 4043-4043.	0.8	15
288	ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, LBA4006-LBA4006.	0.8	5

#	ARTICLE	IF	CITATIONS
289	ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology, 2016, 34, LBA4006-LBA4006.	0.8	21
290	Updated overall survival analysis of NAPOLI-1: Phase III study of nanoliposomal irinotecan (nal-IRI), Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.. Journal of Clinical Oncology, 2016, 34, 417-417.	0.8	6
291	PLATFORM: Planning treatment of oesophago-gastric (OG) cancerâ€”A randomised maintenance therapy trial.. Journal of Clinical Oncology, 2016, 34, TPS187-TPS187.	0.8	4
292	Immunomodulatory switch maintenance therapy in metastatic colorectal carcinoma: The phase III IMPALA study.. Journal of Clinical Oncology, 2016, 34, TPS785-TPS785.	0.8	1
293	Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial. Oncotarget, 2016, 7, 77565-77575.	0.8	12
294	Reduced genomic tumor heterogeneity after neoadjuvant chemotherapy is related to favorable outcome in patients with esophageal adenocarcinoma. Oncotarget, 2016, 7, 44084-44095.	0.8	10
295	Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions. Current Drug Targets, 2016, 18, 56-71.	1.0	25
296	Adjuvant Chemotherapy in Pancreatic Cancer. , 2016, , 1-34.		0
297	Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI), Tj ETQq1 1 0.784314 rgBT /Over cancer (mPAC) previously treated with gemcitabine (gem)-based therapy.. Journal of Clinical Oncology, 2016, 34, 4126-4126.	0.8	0
298	Genome-Wide Methylation Analysis of Patients with Diffuse Large B Cell Lymphoma Treated on the UK NCRI R-CHOP 14 Vs 21 Trial. Blood, 2016, 128, 1747-1747.	0.6	0
299	Transferring genomics to the clinic: distinguishing Burkitt and diffuse large B cell lymphomas. Genome Medicine, 2015, 7, 64.	3.6	20
300	The Role of Routine Clinical Pretreatment 18F-FDG PET/CT in Predicting Outcome of Colorectal Liver Metastasis. Clinical Nuclear Medicine, 2015, 40, e259-e264.	0.7	16
301	A case of metastatic pancreatic adenocarcinoma with prolonged survival after combination of neoadjuvant FOLFIRINOX therapy and synchronous distal pancreatectomy and hepatectomy. Journal of Surgical Oncology, 2015, 111, 768-770.	0.8	10
302	Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. British Journal of Cancer, 2015, 112, 963-970.	2.9	31
303	Pancreatic neuroendocrine tumors: a review. Future Oncology, 2015, 11, 853-864.	1.1	33
304	The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology. European Journal of Cancer, 2015, 51, 2732-2739.	1.3	5
305	Technical Reproducibility of Single-Nucleotide and Size-Based DNA Biomarker Assessment Using DNA Extracted from Formalin-Fixed, Paraffin-Embedded Tissues. Journal of Molecular Diagnostics, 2015, 17, 242-250.	1.2	8
306	Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. European Journal of Cancer, 2015, 51, 18-26.	1.3	21

#	ARTICLE	IF	CITATIONS
307	Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. <i>Lancet Oncology</i> , 2015, 16, 967-978.	5.1	221
308	Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer. <i>British Journal of Cancer</i> , 2015, 113, 603-610.	2.9	30
309	Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 303-312.	0.4	21
310	Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. <i>Annals of Oncology</i> , 2015, 26, 1936-1941.	0.6	24
311	Cetuximab Is Contraindicated in the Perioperative Treatment of Colorectal Liver Metastases. <i>Journal of Clinical Oncology</i> , 2015, 33, 2405-2406.	0.8	7
312	Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): The Royal Marsden Hospital (RMH) experience. <i>BMC Cancer</i> , 2015, 15, 15.	1.1	35
313	The Preoperative Lymphocyte-to-Monocyte Ratio is Prognostic of Clinical Outcomes for Patients with Liver-Only Colorectal Metastases in the Neoadjuvant Setting. <i>Annals of Surgical Oncology</i> , 2015, 22, 4353-4362.	0.7	47
314	Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 318-336.	2.0	18
315	Reply to R.C. Turkington et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 1089-1090.	0.8	0
316	A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv258.	3.0	72
317	Epirubicin, Cisplatin, and Capecitabine Versus Fluorouracil, Leucovorin, and Irinotecan for Esophagogastric Cancer: The Original and the Rest. <i>Journal of Clinical Oncology</i> , 2015, 33, 2409-2409.	0.8	7
318	Caution in the Use of Immunohistochemistry for Determination of Cell of Origin in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 3215-3216.	0.8	7
319	Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2015, 94, 219-226.	1.1	11
320	Adjuvant or neoadjuvant therapy for operable esophagogastric cancer?. <i>Gastric Cancer</i> , 2015, 18, 1-10.	2.7	21
321	R-CHOP in Primary Mediastinal B-Cell Lymphoma (PMBL): Results from the UK NCRI R-CHOP 14 v 21 Trial. <i>Blood</i> , 2015, 126, 2689-2689.	0.6	3
322	Results of the Mantle Cell Lymphoma Subset from a Phase 2a Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent and Aggressive Lymphoma. <i>Blood</i> , 2015, 126, 3935-3935.	0.6	7
323	Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4000-4000.	0.8	85
324	Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: Results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4002-4002.	0.8	59

#	ARTICLE	IF	CITATIONS
325	Effect of TP53 mutation status on survival in the MAGIC trial.. Journal of Clinical Oncology, 2015, 33, 71-71.	0.8	1
326	Long-term Disease-free Survival Following Combination Multi-visceral and Metastatic Resection with Neoadjuvant FOLFIRINOX for Pancreatic Adenocarcinoma: A Case Report. Cureus, 2015, 7, e429.	0.2	3
327	Abstract 3589: Validation of the role of circulating tumor DNA (ctDNA) in tracking mechanisms of resistance to anti-EGFR monoclonal antibodies (AE-mABs): preliminary results of the PROSPECT-C prospective trial. , 2015, , .		0
328	Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Subgroup Analysis from the UK NCRI R-CHOP 14 Vs 21 Trial. Blood, 2015, 126, 1516-1516.	0.6	0
329	Improved Survival in Peripheral T-Cell Lymphoma (PTCL) Following Complete Response to First-Line Chemotherapy: 10 Year Experience at the Royal Marsden and the Christie Hospitals 2002-2012. Blood, 2015, 126, 1499-1499.	0.6	0
330	An Unusual Recurrence of Signet Ring Cell Gastric Adenocarcinoma Treated by Right Hemicolectomy, Pancreaticoduodenectomy, and IVC Resection: Controversies and Dilemmas of Following Standard Treatment Pathways. Cureus, 2015, 7, e424.	0.2	0
331	Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors. OncoTargets and Therapy, 2014, 7, 1001.	1.0	96
332	Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor. Medical Oncology, 2014, 31, 239.	1.2	79
333	Anti-angiogenic therapies for advanced esophago-gastric cancer. Indian Journal of Medical and Paediatric Oncology, 2014, 35, 253-262.	0.1	12
334	Druggable Genetic Dependencies for Molecularly Defined Subgroups of Oesophageal Cancer Identified From High-Throughput Functional Profiling. Annals of Oncology, 2014, 25, ii11.	0.6	0
335	Potential role of rilotumumab in the treatment of gastric cancer. Immunotherapy, 2014, 6, 1243-1253.	1.0	3
336	Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial. Annals of Oncology, 2014, 25, 1616-1622.	0.6	44
337	Risk of Premature Menopause After Treatment for Hodgkin's Lymphoma. Journal of the National Cancer Institute, 2014, 106, .	3.0	48
338	Neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer. Future Oncology, 2014, 10, 2243-2257.	1.1	15
339	<sc>CD</sc>4-positive small T-cell lymphoma of the intestine presenting with severe bile acid malabsorption: a supportive symptom control approach. British Journal of Haematology, 2014, 167, 265-269.	1.2	13
340	Optimal Management of Esophageal Adenocarcinoma: Should We Be CROSS?. Journal of Clinical Oncology, 2014, 32, 3080-3081.	0.8	6
341	Tumor Stage After Neoadjuvant Chemotherapy Determines Survival After Surgery for Adenocarcinoma of the Esophagus and Esophagogastric Junction. Journal of Clinical Oncology, 2014, 32, 2983-2990.	0.8	213
342	<i>Fc</i>R1la</i> and <i>Fc</i>R1b</i> Polymorphisms and Cetuximab Benefit in the Microscopic Disease. Clinical Cancer Research, 2014, 20, 4511-4519.	3.2	7

#	ARTICLE	IF	CITATIONS
343	The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study. <i>European Journal of Cancer</i> , 2014, 50, 1422-1429.	1.3	28
344	Capecitabine and streptozocin±cisplatin in advanced gastroenteropancreatic neuroendocrine tumours. <i>European Journal of Cancer</i> , 2014, 50, 902-911.	1.3	56
345	Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 424-435.	5.1	304
346	Gastric cancer: ESMO“ESSO“ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Radiotherapy and Oncology</i> , 2014, 110, 189-194.	0.3	27
347	Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unit. <i>Gastric Cancer</i> , 2014, 17, 621-629.	2.7	7
348	The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 175-183.	2.0	80
349	GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma. <i>Annals of Hematology</i> , 2014, 93, 827-834.	0.8	8
350	Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. <i>Annals of Oncology</i> , 2014, 25, 1346-1355.	0.6	462
351	RAS mutations and cetuximab in locally advanced rectal cancer: Results of the EXPERT-C trial. <i>European Journal of Cancer</i> , 2014, 50, 1430-1436.	1.3	29
352	FOLFIRINOX for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: The Royal Marsden Experience. <i>Clinical Colorectal Cancer</i> , 2014, 13, 232-238.	1.0	60
353	Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1224-1235.	5.1	1,932
354	Cardiac complications and manifestations of chemotherapy for cancer. <i>Heart</i> , 2014, 100, 1133-1140.	1.2	14
355	Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 504-512.	0.8	351
356	Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 829-840.	5.1	296
357	Does rectal cancer height influence the oncological outcome?. <i>Colorectal Disease</i> , 2014, 16, 801-808.	0.7	16
358	Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients. <i>Medical Oncology</i> , 2014, 31, 166.	1.2	43
359	TP53 Mutational Status and Cetuximab Benefit in Rectal Cancer: 5-Year Results of the EXPERT-C Trial. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	46
360	Cetuximab or bevacizumab in metastatic colorectal cancer?. <i>Lancet Oncology</i> , The, 2014, 15, 1040-1041.	5.1	13

#	ARTICLE	IF	CITATIONS
361	Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2014, 135, 731-741.	2.3	27
362	Bevacizumab in elderly patients with metastatic colorectal cancer. <i>Journal of Geriatric Oncology</i> , 2014, 5, 78-88.	0.5	21
363	Gastric cancer: ESMO's ESSENTRO clinical practice guidelines for diagnosis, treatment and follow-up. <i>European Journal of Surgical Oncology</i> , 2014, 40, 584-591.	0.5	162
364	Correlation of Lactate Dehydrogenase Isoenzyme Profile With Outcome in Patients With Advanced Colorectal Cancer Treated With Chemotherapy and Bevacizumab or Cediranib: Retrospective Analysis of the HORIZON I Study. <i>Clinical Colorectal Cancer</i> , 2014, 13, 46-53.	1.0	22
365	Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 78-86.	5.1	516
366	Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 601-611.	5.1	371
367	A Pilot Study Assessing the Incidence and Clinical Significance of Circulating Tumor Cells in Esophagogastric Cancers. <i>Clinical Colorectal Cancer</i> , 2014, 13, 94-99.	1.0	28
368	Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers. <i>Oncogene</i> , 2014, 33, 966-976.	2.6	44
369	Phase 2A Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent Lymphoma. <i>Blood</i> , 2014, 124, 1701-1701.	0.6	13
370	Is Stem Cell Transplantation for Transformed Follicular Lymphoma Required in the Rituximab Era?: The Royal Marsden Experience 2003-2013. <i>Blood</i> , 2014, 124, 1719-1719.	0.6	1
371	Risk of CNS Relapse with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Trial. <i>Blood</i> , 2014, 124, 1723-1723.	0.6	2
372	A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies. <i>Blood</i> , 2014, 124, 4417-4417.	0.6	7
373	Correlation of PI3KCA and extended RAS gene mutation status with outcomes from the phase III AGITG MAX involving capecitabine (C) alone or in combination with bevacizumab (B) with or without mitomycin C (M) in advanced colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3539-3539.	0.8	2
374	Patterns of progression, treatment of progressive disease, and postprogression survival in the new EPOC study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3556-3556.	0.8	3
375	Analysis of progression-free survival in the new EPOC study in an 'all wild-type' population.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3566-3566.	0.8	1
376	Panex: A pooled analysis of EXPERT and EXPERT-C, two trials of neoadjuvant chemotherapy (NACT) and chemoradiotherapy (CRT) in high-risk locally advanced rectal cancer (LARC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3575-3575.	0.8	7
377	The consistency of effect of ziv-aflibercept (Z) in the bevacizumab (B) pre-treated subgroup of patients (pts) in the velour trial stratified by first-line progression $\geq 9$ months (mos) versus $< 9$ mos.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3639-3639.	0.8	2
378	ABC-03: A randomized phase II trial of cediranib (AZD2171) or placebo in combination with cisplatin/gemcitabine (CisGem) chemotherapy for patients (pts) with advanced biliary tract cancer (ABC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4002-4002.	0.8	3

#	ARTICLE	IF	CITATIONS
379	Toxicity, surgical complications, and short-term mortality in a randomized trial of neoadjuvant cisplatin/5FU versus epirubicin/cisplatin and capecitabine prior to resection of lower esophageal/gastroesophageal junction (GOJ) adenocarcinoma (MRC OEO5, ISRCTN01852072, CRUK Tj ETQq1 1 0.784314 4 rgBT /Over	0.8	4
380	RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma: Quality-of-life (QoL) results.. Journal of Clinical Oncology, 2014, 32, 4058-4058.	0.8	7
381	Quality of life (QoL) analysis from the randomized phase III REAL3 trial of epirubicin, oxaliplatin, and capecitabine (EOC) with or without panitumumab (P) in advanced esophagogastric adenocarcinoma.. Journal of Clinical Oncology, 2014, 32, 4067-4067.	0.8	2
382	RAINBOW: A global, phase 3, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy: Results of a multiple Cox regression analysis adjusting for prognostic factors.. Journal of Clinical Oncology, 2014, 32, 4076-4076.	0.8	13
383	Predictive cytokine biomarkers for survival in patients with advanced pancreatic cancer randomized to sequential chemoimmunotherapy comprising gemcitabine and capecitabine (GemCap) followed by the telomerase vaccine GV1001 compared to concurrent chemoimmunotherapy in the TeloVac phase III trial.. Journal of Clinical Oncology, 2014, 32, 4121-4121.	0.8	4
384	The clinical effectiveness and cost-effectiveness of ablative therapies in the management of liver metastases: systematic review and economic evaluation. Health Technology Assessment, 2014, 18, vii-viii, 1-283.	1.3	43
385	Operable gastro-oesophageal junctional adenocarcinoma: Where to next?. World Journal of Gastrointestinal Oncology, 2014, 6, 145.	0.8	2
386	Fifteen-year experience of all patients (pts) with small bowel adenocarcinoma (SBA), treated in a specialized gastrointestinal (GI) oncology unit: Royal Marsden (RM) experience.. Journal of Clinical Oncology, 2014, 32, 316-316.	0.8	0
387	LEGEND: A randomised phase II study comparing lenalidomide plus rituximab, gemcitabine, and methylprednisolone (R-GEM-L) to rituximab, gemcitabine, methylprednisolone, and cisplatin (R-GEM-P) in second-line treatment of diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2014, 32, TPS8618-TPS8618.	0.8	0
388	MAGIC germline polymorphism analysis.. Journal of Clinical Oncology, 2014, 32, 4068-4068.	0.8	0
389	Abstract 2997: Vessel co-option in colorectal cancer liver metastases mediates resistance to VEGF-targeted therapy. , 2014, , .		0
390	Abstract 2931: Cancer cells deficient in DNA mismatch repair (MMR) are selectively sensitive to inhibition of the DNA dependent protein kinase (DNA-PK). , 2014, , .		0
391	Residual Disease on FDG-PET and Multiple Lines of Prior Therapy Predict Poorer Outcomes Following Autologous Hematopoietic Stem Cell Transplantation for Lymphoma. Blood, 2014, 124, 3971-3971.	0.6	0
392	Successful Long-Term Outcomes in Patients with Lymphoma Achieving Only Partial Response on [18f]FDG-PET Prior to Allogeneic Transplant. Blood, 2014, 124, 1249-1249.	0.6	0
393	The genomic landscape of oesophagogastric junctional adenocarcinoma. Journal of Pathology, 2013, 231, 301-310.	2.1	42
394	Outcome of second-line chemotherapy for biliary tract cancer. European Journal of Cancer, 2013, 49, 1511.	1.3	45
395	Evaluation of regorafenib in colorectal cancer and GIST. Lancet, The, 2013, 381, 273-275.	6.3	29
396	Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials. European Journal of Cancer, 2013, 49, 2116-2125.	1.3	38

#	ARTICLE	IF	CITATIONS
397	Defining treatment standards and novel insights into disease biology. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 73-74.	12.5	33
398	Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 1077-1085.	5.1	550
399	Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. <i>Annals of Oncology</i> , 2013, 24, 1253-1261.	0.6	76
400	Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour cells by enhancing levels of intracellular oxidative stress. <i>British Journal of Cancer</i> , 2013, 108, 983-992.	2.9	29
401	Chronic metastatic pancreatic acinar cell carcinoma. <i>Pancreatology</i> , 2013, 13, 549-552.	0.5	16
402	Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. <i>Lancet Oncology</i> , The, 2013, 14, 627-637.	5.1	346
403	Perioperative Chemotherapy With or Without Bevacizumab in Patients With Metastatic Colorectal Cancer Undergoing Liver Resection. <i>Clinical Colorectal Cancer</i> , 2013, 12, 15-22.	1.0	22
404	Factors affecting survival in patients aged 60 and over with diffuse large B cell lymphoma failing first-line therapy. <i>Journal of Geriatric Oncology</i> , 2013, 4, 134-140.	0.5	5
405	Noninvasive Phosphorus Magnetic Resonance Spectroscopic Imaging Predicts Outcome to First-line Chemotherapy in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma. <i>Academic Radiology</i> , 2013, 20, 1122-1129.	1.3	9
406	Comparison of long-term survival outcome of operative vs nonoperative management of recurrent rectal cancer. <i>Colorectal Disease</i> , 2013, 15, 156-163.	0.7	39
407	Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. <i>Lancet</i> , The, 2013, 381, 1817-1826.	6.3	450
408	Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 481-489.	5.1	631
409	Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2x2 factorial trial. <i>Lancet Oncology</i> , The, 2013, 14, 516-524.	5.1	580
410	Current opinion on optimal treatment for colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 597-611.	1.1	30
411	Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors. <i>British Journal of Cancer</i> , 2013, 108, 2399-2406.	2.9	49
412	Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report. <i>Annals of Oncology</i> , 2013, 24, 702-709.	0.6	64
413	Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2013, 108, 493-502.	2.9	43
414	Panitumumab FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer. <i>New England Journal of Medicine</i> , 2013, 369, 1023-1034.	13.9	1,971



#	ARTICLE	IF	CITATIONS
415	Patupilone in patients with pretreated metastatic/locally recurrent colorectal cancer: results of the Phase II CINATRA trial. <i>Investigational New Drugs</i> , 2013, 31, 1339-1344.	1.2	8
416	Non-operative management for locally advanced rectal cancer: critical review and future perspective. <i>Colorectal Cancer</i> , 2013, 2, 359-370.	0.8	0
417	HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. <i>Annals of Oncology</i> , 2013, 24, 3123-3128.	0.6	32
418	The role of pre-treatment diffusion-weighted MRI in predicting long-term outcome of colorectal liver metastasis. <i>British Journal of Radiology</i> , 2013, 86, 20130281.	1.0	32
419	Discordance between cancer prevalence and training: a need for an increase in oncology education. <i>Clinical Medicine</i> , 2013, 13, 50-56.	0.8	28
420	Gemcitabine Plus Capecitabine in Unselected Patients With Advanced Pancreatic Cancer. <i>Pancreas</i> , 2013, 42, 511-515.	0.5	9
421	Selecting Patients With Locally Advanced Rectal Cancer for Neoadjuvant Treatment Strategies. <i>Oncologist</i> , 2013, 18, 833-842.	1.9	12
422	A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. <i>Annals of Oncology</i> , 2013, 24, 1567-1573.	0.6	98
423	The role of personalized medicine in metastatic colorectal cancer: an evolving landscape. <i>Therapeutic Advances in Gastroenterology</i> , 2013, 6, 381-395.	1.4	33
424	Targeting the PI3K-AKT-mTOR signaling network in cancer. <i>Chinese Journal of Cancer</i> , 2013, 32, 253-265.	4.9	173
425	A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in <i>k</i> -RAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3504-3504.	0.8	34
426	Analysis of <i>KRAS/NRAS</i> and <i>BRAF</i> mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC). <i>Journal of Clinical Oncology</i> , 2013, 31, 3511-3511.	0.8	43
427	Overall survival (OS) analysis from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC). <i>Journal of Clinical Oncology</i> , 2013, 31, 3620-3620.	0.8	8
428	MAGIC trial gene expression profiling study. <i>Journal of Clinical Oncology</i> , 2013, 31, 4020-4020.	0.8	3
429	Cougar-02: A randomized phase III study of docetaxel versus active symptom control in patients with relapsed esophago-gastric adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 4023-4023.	0.8	10
430	HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. <i>Journal of Clinical Oncology</i> , 2013, 31, e14616-e14616.	0.8	1
431	FGFR: Proof-of-concept study of AZD4547 in patients with FGFR1 or FGFR2 amplified tumours. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS2626-TPS2626.	0.8	5
432	RILOMET-1: An international phase III multicenter, randomized, double-blind, placebo-controlled trial of rilotumumab plus epirubicin, cisplatin, and capecitabine (ECX) as first-line therapy in patients with advanced MET-positive gastric or gastroesophageal junction (G/GE) adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS4153-TPS4153.	0.8	12

#	ARTICLE	IF	CITATIONS
433	ST03: A randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with operable gastric, esophagogastric junction (OGJ), or lower esophageal adenocarcinoma.. Journal of Clinical Oncology, 2013, 31, TPS4156-TPS4156.	0.8	1
434	A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer.. Journal of Clinical Oncology, 2013, 31, LBA4004-LBA4004.	0.8	13
435	Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX).. Journal of Clinical Oncology, 2013, 31, 337-337.	0.8	16
436	HER-2 in high risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.. Journal of Clinical Oncology, 2013, 31, 420-420.	0.8	2
437	SCOPE 1: A phase II/III trial of chemoradiotherapy in esophageal cancer plus or minus cetuximab.. Journal of Clinical Oncology, 2013, 31, LBA3-LBA3.	0.8	4
438	COUGAR-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma.. Journal of Clinical Oncology, 2013, 31, LBA4-LBA4.	0.8	14
439	Outcome of patients (pts) with relapsed, advanced upper gastrointestinal (GI) carcinoma treated in a specialist oncology phase I unit.. Journal of Clinical Oncology, 2013, 31, 45-45.	0.8	0
440	Association of high-throughput RNAi and drug screening with candidate novel therapeutic targets in esophageal carcinoma.. Journal of Clinical Oncology, 2013, 31, 31-31.	0.8	0
441	Reporting of subgroup analyses (SGA) in phase III randomized trials in gastrointestinal (GI) cancer.. Journal of Clinical Oncology, 2013, 31, 78-78.	0.8	0
442	Rituximab, gemcitabine, cisplatin, and methylprednisolone (R-GEM-P) in treatment of relapsed diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2013, 31, e19543-e19543.	0.8	0
443	Tumor-related and treatment-related colostomy-free survival (CFS) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance 5FU/CisP chemotherapy (CT) in squamous cell carcinoma of the anus (SCCA): Results of ACT II.. Journal of Clinical Oncology, 2013, 31, 3532-3532.	0.8	1
444	A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer.. Journal of Clinical Oncology, 2013, 31, LBA4004-LBA4004.	0.8	4
445	Efficacy and safety according to age subgroups in AVEX, a randomized phase III trial of bevacizumab in combination with capecitabine for the first-line treatment of elderly patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 3521-3521.	0.8	1
446	A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. Annals of Oncology, 2012, 23, 119-127.	0.6	23
447	Gastrointestinal oncology – what you need to know. Clinical Medicine, 2012, 12, 575-579.	0.8	0
448	A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma. Annals of Oncology, 2012, 23, 942-947.	0.6	12
449	Primary Follicular Lymphoma of the GI Tract: An Increasingly Recognized Entity. Journal of Clinical Oncology, 2012, 30, e370-e372.	0.8	5
450	Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection. British Journal of Cancer, 2012, 106, 1718-1721.	2.9	30

#	ARTICLE	IF	CITATIONS
451	Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study. <i>British Journal of Cancer</i> , 2012, 107, 435-441.	2.9	18
452	Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. <i>Nature Genetics</i> , 2012, 44, 1131-1136.	9.4	162
453	Breast Cancer Risk After Supradiaphragmatic Radiotherapy for Hodgkin's Lymphoma in England and Wales: A National Cohort Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2745-2752.	0.8	142
454	Are We Ready To Stratify Treatment for Diffuse Large B-Cell Lymphoma Using Molecular Hallmarks?. <i>Oncologist</i> , 2012, 17, 1562-1573.	1.9	41
455	Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2012, 5, 301-318.	1.4	44
456	Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. <i>Lancet Oncology</i> , The, 2012, 13, 1225-1233.	5.1	484
457	Impact of targeted neoadjuvant therapies in the treatment of solid organ tumours. <i>British Journal of Surgery</i> , 2012, 100, 5-14.	0.1	5
458	Preoperative and Postoperative Chemotherapy for Gastric Cancer. <i>Surgical Oncology Clinics of North America</i> , 2012, 21, 99-112.	0.6	20
459	The unique entity of nodular lymphocyte-predominant Hodgkin lymphoma: current approaches to diagnosis and management. <i>Leukemia and Lymphoma</i> , 2012, 53, 354-361.	0.6	16
460	Diagnosis and management of rare gastrointestinal lymphomas. <i>Leukemia and Lymphoma</i> , 2012, 53, 2341-2350.	0.6	23
461	Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): Long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin. <i>Radiotherapy and Oncology</i> , 2012, 104, 155-160.	0.3	27
462	Peri-operative chemotherapy in the management of resectable colorectal cancer pulmonary metastases. <i>BMC Cancer</i> , 2012, 12, 326.	1.1	26
463	Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III). <i>Journal of Clinical Oncology</i> , 2012, 30, 3588-3595.	0.8	194
464	Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C). <i>Journal of Clinical Oncology</i> , 2012, 30, 1620-1627.	0.8	357
465	Targeted Therapy for Gastric Cancer. <i>Current Treatment Options in Oncology</i> , 2012, 13, 377-389.	1.3	62
466	Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1635-1646.	3.0	227
467	Toward the Non-surgical Management of Locally Advanced Rectal Cancer. <i>Current Oncology Reports</i> , 2012, 14, 267-276.	1.8	7
468	Molecular analysis of the randomized phase II/III study of the anti-IGF-1R antibody dalotuzumab (MK-0646) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory KRAS wild-type metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 3531-3531.	0.8	8

#	ARTICLE	IF	CITATIONS
469	Activity of the anti-IGF-1R antibody dalotuzumab (MK-0646) in KRAS-mutant colorectal cancer: Preclinical and clinical data.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3587-3587.	0.8	2
470	Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP/5FU in squamous cell carcinoma of the anus: Results of ACT II.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4004-4004.	0.8	30
471	The pattern and timing of disease recurrence in squamous cancer of the anus: Mature results from the NCRI ACT II trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4029-4029.	0.8	14
472	Treatment of advanced neuroendocrine tumors: Results of the UKINETS and NCRI randomized phase II NET01 trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4121-4121.	0.8	3
473	Correlation of lactate dehydrogenase (LDH) isoenzyme profile with outcome in advanced colorectal cancer (CRC) patients (pts) treated with chemotherapy and bevacizumab (BEV) or cediranib (CED).. <i>Journal of Clinical Oncology</i> , 2012, 30, e13541-e13541.	0.8	1
474	A randomized, multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3).. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA4000-LBA4000.	0.8	1
475	A randomized, multicenter, double-blind, placebo (PBO)-controlled phase III study of paclitaxel (PTX) with or without ramucirumab (IMC-1121B; RAM) in patients (pts) with metastatic gastric adenocarcinoma, refractory to or progressive after first-line therapy with platinum (PLT) and fluoropyrimidine (FP).. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS4139-TPS4139.	0.8	4
476	ST03: A randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with operable gastric, oesophagogastric junction (OGJ) or lower oesophageal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS4143-TPS4143.	0.8	9
477	A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3).. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA4000-LBA4000.	0.8	34
478	Elevated CEA level in the asymptomatic patient with normal conventional imaging: How useful is PET-CT for the detection of colorectal cancer recurrence?. <i>Journal of Clinical Oncology</i> , 2012, 30, 400-400.	0.8	1
479	Final skin toxicity (ST) and patient-reported outcomes (PRO) results from PRIME: A randomized phase III study of panitumumab (pmab) plus FOLFOX4 (CT) for first-line metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 531-531.	0.8	6
480	The Value of Source Data Verification in a Cancer Clinical Trial. <i>PLoS ONE</i> , 2012, 7, e51623.	1.1	58
481	Comparison of long-term survival outcomes of operative versus nonoperative management of recurrent rectal cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14132-e14132.	0.8	0
482	The impact of TP53 mutation on high-risk rectal cancer patients treated within the EXPERT-C trial, a randomized phase II study of neoadjuvant oxaliplatin/capecitabine (CAPOX) and chemoradiation (CRT) with or without cetuximab.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14088-e14088.	0.8	0
483	Guidelines for the management of oesophageal and gastric cancer. <i>Gut</i> , 2011, 60, 1449-1472.	6.1	570
484	Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status. <i>Journal of Clinical Oncology</i> , 2011, 29, 2011-2019.	0.8	1,713
485	Targeting the human EGFR family in esophagogastric cancer. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 492-503.	12.5	132
486	Optimal Therapeutic Strategies for Resectable Oesophageal or Oesophagogastric Junction Cancer. <i>Drugs</i> , 2011, 71, 541-555.	4.9	16

#	ARTICLE	IF	CITATIONS
487	Correlation of Overall Survival With Gene Expression Profiles in a Prospective Study of Resectable Esophageal Cancer. <i>Clinical Colorectal Cancer</i> , 2011, 10, 48-56.	1.0	12
488	Nonsurgical Management of Esophageal Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2011, 10, 165-170.	1.0	1
489	Integration of Biologic Agents With Cytotoxic Chemotherapy in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2011, 10, 245-257.	1.0	20
490	Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer. <i>European Journal of Cancer</i> , 2011, 47, 1146-1151.	1.3	29
491	First-line treatment of advanced colorectal cancer. <i>Lancet, The</i> , 2011, 377, 2060-2062.	6.3	16
492	Timing of Surgery Following Preoperative Therapy in Rectal Cancer: The Need for a Prospective Randomized Trial?. <i>Diseases of the Colon and Rectum</i> , 2011, 54, 1251-1259.	0.7	58
493	Simple nutritional intervention in patients with advanced cancers of the gastrointestinal tract, non-small cell lung cancers or mesothelioma and weight loss receiving chemotherapy: a randomised controlled trial. <i>Journal of Human Nutrition and Dietetics</i> , 2011, 24, 431-440.	1.3	103
494	Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction. <i>British Journal of Cancer</i> , 2011, 104, 43-50.	2.9	12
495	Neoadjuvant Chemotherapy Alone for Early-Stage Rectal Cancer: An Evolving Paradigm?. <i>Seminars in Radiation Oncology</i> , 2011, 21, 196-202.	1.0	8
496	Chemotherapy for Operable Gastric Cancer: Current Perspectives. <i>Indian Journal of Surgical Oncology</i> , 2011, 2, 334-342.	0.3	7
497	Perioperative therapy improves gastroesophageal cancer survival. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 450-452.	12.5	2
498	Second Cancer Risk After Chemotherapy for Hodgkin's Lymphoma: A Collaborative British Cohort Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 4096-4104.	0.8	175
499	Targeting Angiogenesis in Esophagogastric Adenocarcinoma. <i>Oncologist</i> , 2011, 16, 844-858.	1.9	44
500	Cardiotoxicity in Patients Treated With Bevacizumab Is Potentially Reversible. <i>Journal of Clinical Oncology</i> , 2011, 29, e560-e562.	0.8	31
501	Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. <i>Annals of Oncology</i> , 2011, 22, 2604-2609.	0.6	75
502	Reply to M. Mohiuddin et al. <i>Journal of Clinical Oncology</i> , 2011, 29, 2737-2738.	0.8	3
503	A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. <i>Annals of Oncology</i> , 2011, 22, 2042-2048.	0.6	197
504	Abstract 350: High-throughput drug screens identify novel synthetic lethal interactions with MLH1-deficient cancers. , 2011, , .		1

#	ARTICLE	IF	CITATIONS
505	First Analysis of a Phase II Study of Rituximab-Gemcitabine, Cyclophosphamide, Vincristine and Prednisolone (R-GCVP) for Diffuse Large B Cell Lymphoma (DLBCL) Patients Considered Unsuited for Anthracycline Containing Chemo-Immunotherapy. An NCRJ Lymphoma Clinical Studies Group Trial. <i>Blood</i> , 2011, 118, 1634-1634.	0.6	2
506	<i>IRF4</i> polymorphism rs872071 and risk of Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2010, 148, 413-415.	1.2	17
507	Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <math>\leq 65\text{ years}</math> with poor prognosis histologically aggressive NHL. <i>British Journal of Haematology</i> , 2010, 149, 237-243.	1.2	15
508	Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status. <i>British Journal of Cancer</i> , 2010, 102, 255-261.	2.9	9
509	Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1073.	3.8	1,206
510	Relationship Between Colorectal Cancer Biomarkers and Response to Epidermal Growth Factor Receptor Monoclonal Antibodies. <i>Journal of Clinical Oncology</i> , 2010, 28, e529-e531.	0.8	23
511	Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. <i>Annals of Oncology</i> , 2010, 21, 2213-2219.	0.6	98
512	Lymphocyte-Predominant Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, e325-e325.	0.8	4
513	Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 3191-3198.	0.8	370
514	Flexible sigmoidoscopy is valuable in colorectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 488-490.	12.5	3
515	Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer. <i>New England Journal of Medicine</i> , 2010, 362, 858-859.	13.9	126
516	The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy. <i>Annals of Oncology</i> , 2010, 21, 1013-1019.	0.6	46
517	Rechallenge with Platinum plus Fluoropyrimidine + Epirubicin in Patients with Oesophagogastric Cancer. <i>Oncology</i> , 2010, 79, 150-158.	0.9	13
518	Optimal treatment of metastatic pancreatic cancer. <i>Gut</i> , 2010, 59, 1454-1455.	6.1	4
519	Perioperative management of esophageal cancer. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 231-238.	12.5	23
520	Predictive and Prognostic Biomarkers for Targeted Therapy in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2010, 9, 274-281.	1.0	63
521	Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008. <i>Clinical Colorectal Cancer</i> , 2010, 9, 8-14.	1.0	7
522	Targeted Therapies as Adjuvant Treatment for Early-Stage Colorectal Cancer: First Impressions and Clinical Questions. <i>Clinical Colorectal Cancer</i> , 2010, 9, S28-S35.	1.0	3

#	ARTICLE	IF	CITATIONS
523	Mismatch repair deficient colorectal cancer in the era of personalized treatment. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 197-208.	12.5	189
524	Lymphocyte-predominant Hodgkin lymphoma—clinical features and treatment outcomes from a 30-year experience. <i>Annals of Oncology</i> , 2010, 21, 2061-2068.	0.6	60
525	Epirubicin, Oxaliplatin, and Capecitabine With or Without Panitumumab for Advanced Esophagogastric Cancer: Dose-Finding Study for the Prospective Multicenter, Randomized, Phase II/III REAL-3 Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 3945-3950.	0.8	118
526	Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 4697-4705.	0.8	1,644
527	Prognostic Role of <i>KRAS</i> and <i>BRAF</i> in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 466-474.	0.8	1,048
528	Trastuzumab in gastric cancer. <i>European Journal of Cancer</i> , 2010, 46, 1949-1959.	1.3	66
529	Colorectal cancer. <i>Lancet, The</i> , 2010, 375, 1030-1047.	6.3	1,318
530	Colorectal cancer — Authors' reply. <i>Lancet, The</i> , 2010, 376, 331-332.	6.3	17
531	Trastuzumab for gastric cancer treatment. <i>Lancet, The</i> , 2010, 376, 1736.	6.3	6
532	Chemotherapy: Adjuvant and Neoadjuvant Approaches. , 2010, , 175-187.		0
533	Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. <i>Lancet Oncology, The</i> , 2010, 11, 241-248.	5.1	305
534	Are we ready to restrict EGFR therapy to quadruple-negative colorectal cancer?. <i>Lancet Oncology, The</i> , 2010, 11, 1020-1021.	5.1	2
535	Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. <i>New England Journal of Medicine</i> , 2010, 362, 1273-1281.	13.9	3,370
536	Chemotherapy for Advanced Pancreatic Cancer. , 2010, , 913-949.		1
537	Adjuvant Chemotherapy in Pancreatic Cancer. , 2010, , 1051-1077.		2
538	An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy In Patients with Stage II, III, IV, Asymptomatic, Non-Bulky Follicular Lymphoma (Grades 1, 2 and 3a). A Preliminary Analysis. <i>Blood</i> , 2010, 116, 6-6.	0.6	65
539	Phosphorus Magnetic Resonance Spectroscopy Predicts Outcome to Chemotherapy In Patients with Diffuse Large B-Cell Lymphoma: A Prospective International Multicenter Analysis of a Pretreatment Metabolic Biomarker of Response. <i>Blood</i> , 2010, 116, 3104-3104.	0.6	0
540	Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5513-5518.	0.8	708

#	ARTICLE	IF	CITATIONS
541	Optimizing irinotecan regimens for colorectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 560-561.	12.5	8
542	Utility of the Follicular Lymphoma International Prognostic Index and the International Prognostic Index in Assessing Prognosis and Predicting First-Line Treatment Efficacy in Follicular Lymphoma Patients. <i>Acta Haematologica</i> , 2009, 122, 193-199.	0.7	13
543	Thromboembolism in Patients With Advanced Gastroesophageal Cancer Treated With Anthracycline, Platinum, and Fluoropyrimidine Combination Chemotherapy: A Report From the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. <i>Journal of Clinical Oncology</i> , 2009, 27, 3786-3793.	0.8	155
544	The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma—individual patient data from 1775 patients in four randomised controlled trials. <i>Annals of Oncology</i> , 2009, 20, 885-891.	0.6	50
545	Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. <i>Journal of Clinical Oncology</i> , 2009, 27, 5390-5396.	0.8	164
546	Dose Finding and Early Efficacy Study of Gemcitabine Plus Capecitabine in Combination With Bevacizumab Plus Erlotinib in Advanced Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5499-5505.	0.8	23
547	Validation of the Royal Marsden Hospital Prognostic Index in Advanced Esophagogastric Cancer Using Individual Patient Data From the REAL 2 Study. <i>Journal of Clinical Oncology</i> , 2009, 27, e3-e4.	0.8	46
548	Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3. <i>Journal of Clinical Oncology</i> , 2009, 27, 3117-3125.	0.8	437
549	Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2009, 20, 244-250.	0.6	49
550	Optimising treatment regimens for the management of advanced gastric cancer. <i>Annals of Oncology</i> , 2009, 20, 605-608.	0.6	16
551	Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients — analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO. <i>BMC Cancer</i> , 2009, 9, 153.	1.1	25
552	A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 455-462.	1.1	29
553	Treatment in advanced colorectal cancer: what, when and how?. <i>British Journal of Cancer</i> , 2009, 100, 1704-1719.	2.9	89
554	A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma. <i>British Journal of Cancer</i> , 2009, 100, 1725-1730.	2.9	20
555	Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. <i>British Journal of Cancer</i> , 2009, 101, 1033-1038.	2.9	154
556	Current perspective: Bevacizumab in colorectal cancer — A time for reappraisal?. <i>European Journal of Cancer</i> , 2009, 45, 2452-2461.	1.3	34
557	Upper Gastrointestinal Malignancies: A New Era in Clinical Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2009, 8, 185-189.	1.0	1
558	Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. <i>Annals of Oncology</i> , 2009, 20, 1842-1847.	0.6	476



#	ARTICLE	IF	CITATIONS
559	Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. <i>Annals of Oncology</i> , 2009, 20, 1529-1534.	0.6	212
560	Bevacizumab-associated gastrointestinal perforation. <i>Lancet Oncology</i> , The, 2009, 10, 534-536.	5.1	10
561	Longitudinal Assessment of Quality of Life in Rectal Cancer Patients With or Without Stomas Following Primary Resection. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 669-677.	0.7	54
562	Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2009, 4, 54-72.	0.8	125
563	Accomplishments in 2008 in the management of localized gastric cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2009, 3, S48-52.	0.8	1
564	What is the impact of biologicals in colorectal cancer?. <i>Targeted Oncology</i> , 2008, 3, 59-69.	1.7	0
565	Evaluating Mesorectal Lymph Nodes in Rectal Cancer Before and After Neoadjuvant Chemoradiation Using Thin-Section T2-Weighted Magnetic Resonance Imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 456-461.	0.4	126
566	Detection of colorectal hepatic metastases using MnDPDP MR imaging and diffusion-weighted imaging (DWI) alone and in combination. <i>European Radiology</i> , 2008, 18, 903-910.	2.3	145
567	Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. <i>British Journal of Cancer</i> , 2008, 99, 6-13.	2.9	98
568	Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. <i>British Journal of Cancer</i> , 2008, 99, 868-874.	2.9	58
569	Clarifying the TNM staging of rectal cancer in the context of modern imaging and neo-adjuvant treatment: $\gamma$ TM and $\beta$ TM need $\mu$ TM and $\nu$ TM. <i>Colorectal Disease</i> , 2008, 10, 242-243. <sup>0.7</sup>	0.7	32
570	High-grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis. <i>British Journal of Haematology</i> , 2008, 143, 71-74.	1.2	47
571	Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison. <i>BMC Cancer</i> , 2008, 8, 192.	1.1	25
572	Epidermal Growth Factor Receptor Inhibitor-Related Skin Toxicity: Mechanisms, Treatment, and its Potential Role as a Predictive Marker. <i>Clinical Colorectal Cancer</i> , 2008, 7, 33-43.	1.0	53
573	Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy in Advanced Lymphoma: A Phase II Study. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 241-245.	1.4	41
574	Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer. <i>New England Journal of Medicine</i> , 2008, 358, 36-46.	13.9	2,052
575	Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer. <i>European Journal of Cancer</i> , 2008, 44, 652-662.	1.3	4
576	Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. <i>Annals of Oncology</i> , 2008, 19, 1720-1726.	0.6	163

#	ARTICLE	IF	CITATIONS
577	Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines. <i>Journal of Clinical Oncology</i> , 2008, 26, 2118-2123.	0.8	226
578	Using Predictive Biomarkers to Select Patients With Advanced Colorectal Cancer for Treatment With Epidermal Growth Factor Receptor Antibodies. <i>Journal of Clinical Oncology</i> , 2008, 26, 5668-5670.	0.8	83
579	Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2008, 19, 1312-1319.	0.6	117
580	Does combining docetaxel with cisplatin and fluorouracil improve clinical benefit in advanced gastroesophageal cancer?. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 132-133.	4.3	2
581	Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 4579-4586.	0.8	555
582	Results of the 2nd Planned Interim Analysis of the RAPID Trial (involved field radiotherapy versus no) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 FDG-PET Scan after 3 Cycles ABVD. <i>Blood</i> , 2008, 112, 369-369.	0.6	20
583	Randomised Comparison of the Stanford V (SV) Regimen and ABVD in the Treatment of Advanced Hodgkin Lymphoma (HL): Results from a UK NCRI Lymphoma Group Study, ISRCTN 64141244. <i>Blood</i> , 2008, 112, 370-370.	0.6	7
584	Capecitabine in gastric cancer. <i>Drugs of Today</i> , 2008, 44, 629.	0.7	7
585	Stem cell transplantation in Hodgkin lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 297-306.	1.1	9
586	Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL). <i>Hematology</i> , 2007, 12, 149-153.	0.7	13
587	East Meets West in the Treatment of Gastric Cancer. <i>New England Journal of Medicine</i> , 2007, 357, 1863-1865.	13.9	70
588	Paraneoplastic syndrome: Subacute cerebellar degeneration in Hodgkin's disease. <i>Leukemia and Lymphoma</i> , 2007, 48, 819-822.	0.6	3
589	Does shorter duration of chemotherapy worsen survival for elderly patients with colon cancer?. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 12-13.	4.3	1
590	Capecitabine in advanced gastric cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2851-2861.	0.9	4
591	Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 2607-2615.	0.8	387
592	Myocardial Infarction Mortality Risk After Treatment for Hodgkin Disease: A Collaborative British Cohort Study. <i>Journal of the National Cancer Institute</i> , 2007, 99, 206-214.	3.0	411
593	Renal tubular acidosis due to oxaliplatin. <i>Annals of Oncology</i> , 2007, 18, 805-806.	0.6	14
594	The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. <i>Annals of Oncology</i> , 2007, 18, 541-545.	0.6	75

#	ARTICLE	IF	CITATIONS
595	Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naïve advanced colorectal cancer: a phase II study. <i>Annals of Oncology</i> , 2007, 18, 730-737.	0.6	31
596	Adjuvant chemotherapy of colorectal cancer. <i>Lancet</i> , The, 2007, 370, 1980-1981.	6.3	11
597	Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer. <i>Lancet Oncology</i> , The, 2007, 8, 625-633.	5.1	199
598	Chemoradiotherapy alone for rectal cancer: a word of caution – Authors' reply. <i>Lancet Oncology</i> , The, 2007, 8, 862-863.	5.1	1
599	Mucosa associated lymphoid tissue lymphoma of the lung: The Royal Marsden Hospital experience. <i>Leukemia and Lymphoma</i> , 2007, 48, 547-550.	0.6	17
600	Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. <i>Haematologica</i> , 2007, 92, 271-272.	1.7	90
601	Pharmacotherapy for Oesophagogastric Cancer. <i>Drugs</i> , 2007, 67, 2539-2556.	4.9	4
602	Current Treatment Strategies in Elderly Patients with Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2007, 6, 508-515.	1.0	13
603	The Role of Epidermal Growth Factor Receptor-Targeted Antibody Therapy in Previously Treated Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2007, 6, S47-S52.	1.0	1
604	A Retrospective on the Inhibition of Epidermal Growth Factor Receptor as a Therapeutic Strategy for Patients with Relapsed Metastatic Colorectal Cancer: Impact on Treatment of Today's Patients. <i>Clinical Colorectal Cancer</i> , 2007, 7, S8-S15.	1.0	2
605	Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. <i>British Journal of Cancer</i> , 2007, 96, 206-212.	2.9	68
606	The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract. <i>British Journal of Cancer</i> , 2007, 96, 1178-1182.	2.9	46
607	Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. <i>British Journal of Cancer</i> , 2007, 96, 1183-1190.	2.9	212
608	The UK NCRI MAGIC Trial of Perioperative Chemotherapy in Resectable Gastric Cancer: Implications for Clinical Practice. <i>Annals of Surgical Oncology</i> , 2007, 14, 2687-2690.	0.7	56
609	Symptoms and weight loss in patients with gastrointestinal and lung cancer at presentation. <i>Supportive Care in Cancer</i> , 2007, 15, 39-46.	1.0	98
610	Management of Locally Advanced Rectal Cancer. , 2007, , 155-189.		0
611	Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. <i>New England Journal of Medicine</i> , 2006, 355, 11-20.	13.9	5,356
612	Sub-clinical dissemination of follicular lymphoma in normal sized lymph nodes may not be detected by radiologic staging: a case of disseminated follicular lymphoma detected in nodal clearance as part of therapy for cutaneous melanoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 553-556.	0.6	2

#	ARTICLE	IF	CITATIONS
613	Is oxaliplatin the optimal platinum agent in gastric cancer?. European Journal of Cancer, Supplement, 2006, 4, 10-13.	2.2	3
614	Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease. Radiotherapy and Oncology, 2006, 78, 1-5.	0.3	90
615	Neoadjuvant Treatment of Unresectable Liver Metastases from Colorectal Cancer. Clinical Colorectal Cancer, 2006, 5, 405-412.	1.0	6
616	Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imagingâ€”Defined Poor-Risk Rectal Cancer. Journal of Clinical Oncology, 2006, 24, 668-674.	0.8	432
617	Parainfluenza type 3 infection post stem cell transplant: high prevalence but low mortality. Journal of Hospital Infection, 2006, 63, 452-458.	1.4	26
618	MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive circumferential margins?. British Journal of Cancer, 2006, 94, 351-357.	2.9	266
619	A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma. British Journal of Cancer, 2006, 94, 806-813.	2.9	36
620	Reply: Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. British Journal of Cancer, 2006, 94, 937-937.	2.9	0
621	Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. British Journal of Cancer, 2006, 94, 1107-1115.	2.9	71
622	Chemotherapy for advanced pancreatic cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2006, 20, 327-348.	1.0	20
623	5-Fluorouracil can cross brainâ€”blood barrier and cause encephalopathy: should we expect the same from capecitabine? A case report on capecitabine-induced central neurotoxicity progressing to coma. Cancer Chemotherapy and Pharmacology, 2006, 58, 276-278.	1.1	51
624	Potential of Surface-Coil MRI for Staging of Esophageal Cancer. American Journal of Roentgenology, 2006, 187, 1280-1287.	1.0	46
625	Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer. Annals of Oncology, 2006, 17, 437-442.	0.6	27
626	Adjuvant therapy in colon cancerâ€”what, when and how?. Annals of Oncology, 2006, 17, 1347-1359.	0.6	142
627	MRI in predicting curative resection of rectal cancer: New dilemma in multidisciplinary team management. BMJ: British Medical Journal, 2006, 333, 808.1.	2.4	12
628	Panitumumab. Drugs of Today, 2006, 42, 711.	0.7	20
629	Role of erlotinib in the management of pancreatic cancer. Therapeutics and Clinical Risk Management, 2006, 2, 435-445.	0.9	23
630	What Is the Role of Mitomycin C in Advanced Gastric Cancer?. Oncology Research and Treatment, 2005, 28, 125-126.	0.8	0

#	ARTICLE	IF	CITATIONS
631	CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. <i>Blood</i> , 2005, 105, 1417-1423.	0.6	896
632	Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2005, 130, 536-541.	1.2	18
633	Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. <i>British Journal of Cancer</i> , 2005, 92, 1352-1357.	2.9	56
634	Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. <i>British Journal of Cancer</i> , 2005, 92, 1976-1983.	2.9	138
635	Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. <i>British Journal of Cancer</i> , 2005, 92, 1650-1654.	2.9	137
636	Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. <i>British Journal of Cancer</i> , 2005, 93, 510-514.	2.9	58
637	CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. <i>British Journal of Cancer</i> , 2005, 93, 740-743.	2.9	139
638	The palatability of milk-based and non-milk-based nutritional supplements in gastrointestinal cancer and the effect of chemotherapy. <i>Clinical Nutrition</i> , 2005, 24, 1029-1037.	2.3	41
639	The Role of Cetuximab in the Therapy of Previously Treated Advanced Colorectal Cancer. <i>Seminars in Oncology</i> , 2005, 32, 55-58.	0.8	6
640	Second-line therapy for advanced colorectal cancer. <i>Current Colorectal Cancer Reports</i> , 2005, 1, 7-12.	1.0	0
641	Second-line therapy for advanced colorectal carcinoma. <i>Current Oncology Reports</i> , 2005, 7, 173-180.	1.8	3
642	The role of preoperative chemotherapy for esophageal cancer: when is surgery alone feasible?. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 172-173.	4.3	4
643	Adjuvant Treatment for Resectable Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 4532-4537.	0.8	67
644	The effects of capecitabine in Raynaud's disease: a case report. <i>Annals of Oncology</i> , 2005, 16, 835-836.	0.6	6
645	Definition of disease-free survival: this is my truthâ€“show me yours. <i>Annals of Oncology</i> , 2005, 16, 1719-1721.	0.6	27
646	Improving Long-Term Outcomes for Patients With Liver Metastases From Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 9063-9066.	0.8	49
647	Managing Patients Treated with Bevacizumab Combination Therapy. <i>Oncology</i> , 2005, 69, 25-33.	0.9	265
648	A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. <i>Annals of Oncology</i> , 2005, 16, 549-557.	0.6	168

#	ARTICLE	IF	CITATIONS
649	Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. <i>Blood</i> , 2005, 105, 397-404.	0.6	107
650	Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. <i>Annals of Oncology</i> , 2005, 16, 1305-1310.	0.6	136
651	Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer. <i>European Journal of Cancer</i> , 2005, 41, 1551-1559.	1.3	20
652	The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). <i>European Journal of Cancer</i> , 2005, 41, 1542-1546.	1.3	118
653	Cetuximab in Previously Treated Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2005, 5, S28-S33.	1.0	9
654	Recent Data with Anti-epidermal Growth Factor Receptor Antibodies and Irinotecan in Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2005, 5, S81-S88.	1.0	7
655	Mabthera (Rituximab) Plus CVP Chemotherapy for First-Line Treatment of Stage III/IV Follicular Non-Hodgkin's Lymphoma (NHL): Confirmed Efficacy with Longer Follow-Up.. <i>Blood</i> , 2005, 106, 350-350.	0.6	8
656	Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. <i>Annals of Oncology</i> , 2004, 15, 1330-1338.	0.6	230
657	Tumour vaccine associated lymphadenopathy and false positive positron emission tomography scan changes. <i>British Journal of Radiology</i> , 2004, 77, 74-75.	1.0	35
658	MALT Lymphoma of the Foreskin. <i>Leukemia and Lymphoma</i> , 2004, 45, 1699-1701.	0.6	14
659	Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2004, 15, 1413-1418.	0.6	41
660	A Randomized Trial Comparing Defined-Duration With Continuous Irinotecan Until Disease Progression in Fluoropyrimidine and Thymidylate Synthase Inhibitor-Resistant Advanced Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 3023-3031.	0.8	42
661	Phase III Double-Blind Placebo-Controlled Study of Farnesyl Transferase Inhibitor R115777 in Patients With Refractory Advanced Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 3950-3957.	0.8	232
662	Multivariate Prognostic Factor Analysis in Locally Advanced and Metastatic Esophago-Gastric Cancer-Pooled Analysis From Three Multicenter, Randomized, Controlled Trials Using Individual Patient Data. <i>Journal of Clinical Oncology</i> , 2004, 22, 2395-2403.	0.8	455
663	Fludarabine, adriamycin and dexamethasone (FAD) in newly diagnosed advanced follicular lymphoma: a phase II study by the British National Lymphoma Investigation (BNLI). <i>British Journal of Cancer</i> , 2004, 91, 695-698.	2.9	4
664	Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. <i>British Journal of Cancer</i> , 2004, 90, 1190-1197.	2.9	368
665	Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. <i>Annals of Oncology</i> , 2004, 15, 1013-1017.	0.6	106
666	The Value of Routine Serum Carcino-Embryonic Antigen Measurement and Computed Tomography in the Surveillance of Patients After Adjuvant Chemotherapy for Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 1420-1429.	0.8	153

#	ARTICLE	IF	CITATIONS
667	Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. <i>British Journal of Cancer</i> , 2004, 91, 839-843.	2.9	33
668	Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. <i>British Journal of Cancer</i> , 2004, 91, 1453-1458.	2.9	67
669	Phase III Study of Mitomycin-C with Protracted Venous Infusion or Circadian-Timed Infusion of 5-Fluorouracil in Advanced Colorectal Carcinoma. <i>Clinical Colorectal Cancer</i> , 2004, 3, 235-242.	1.0	29
670	A Retrospective Study of Resection of Pulmonary Metastases in Patients wit Advanced Colorectal Cancer: The Development of a PreoperativeChemotherapy Strategy. <i>Clinical Colorectal Cancer</i> , 2004, 4, 101-106.	1.0	25
671	Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2004, 351, 337-345.	13.9	4,721
672	Sixty-day all-cause mortality rates in patients treated for gastrointestinal cancers, in randomised trials, at the Royal Marsden Hospital. <i>European Journal of Cancer</i> , 2004, 40, 2230-2236.	1.3	12
673	Monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor in advanced colorectal cancers: present and future directions. <i>Current Opinion in Oncology</i> , 2004, 16, 385-390.	1.1	27
674	Systemic treatment of gastric cancer. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 255-263.	0.8	51
675	Matrix metalloproteinase inhibitors— an emphasis on gastrointestinal malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 45, 151-176.	2.0	23
676	Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2003, 120, 970-977.	1.2	56
677	Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil. <i>British Journal of Cancer</i> , 2003, 88, 1510-1515.	2.9	16
678	Overview of Preoperative and Postoperative Therapy for Colorectal Cancer: The European and United States Perspectives. <i>Clinical Colorectal Cancer</i> , 2003, 3, 19-33.	1.0	32
679	Impact of 5-Fluorouracil Rechallenge on Subsequent Response and Survival in Advanced Colorectal Cancer: Pooled Analysis from Three Consecutive Randomized Controlled Trials. <i>Clinical Colorectal Cancer</i> , 2003, 3, 102-107.	1.0	9
680	Clinical and Molecular Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated with 5-Fluorouracil-Based Chemotherapy. <i>Clinical Colorectal Cancer</i> , 2003, 2, 235-238.	1.0	0
681	The Role of Surveillance CT Scans in Patients with Diffuse Large B-cell Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2003, 44, 123-125.	0.6	74
682	Mutant K-ras2 in serum. <i>Gut</i> , 2003, 52, 915-a-916.	6.1	3
683	Oxaliplatin for Colorectal Cancer in the United States: Better Late Than Never. <i>Journal of Clinical Oncology</i> , 2003, 21, 2049-2051.	0.8	14
684	A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer. <i>Annals of Oncology</i> , 2003, 14, 1264-1269.	0.6	28

#	ARTICLE	IF	CITATIONS
685	Adjuvant therapy in pancreatic cancer: historical and current perspectives. <i>Annals of Oncology</i> , 2003, 14, 675-692.	0.6	115
686	Reply 2: NICE guidelines on drugs for colorectal cancer. <i>British Journal of Cancer</i> , 2003, 88, 1154-1155.	2.9	0
687	Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer. <i>British Journal of Cancer</i> , 2003, 88, 1017-1024.	2.9	78
688	Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?. <i>British Journal of Cancer</i> , 2003, 89, 36-42.	2.9	68
689	Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. <i>British Journal of Cancer</i> , 2003, 88, 1859-1865.	2.9	78
690	Adjuvant Therapy for Colon Cancer in the New Millenium. <i>Scandinavian Journal of Surgery</i> , 2003, 92, 57-64.	1.3	6
691	Molecular pharmacology of cancer therapy in human colorectal cancer by gene expression profiling. <i>Cancer Research</i> , 2003, 63, 6855-63.	0.4	27
692	Early <i>in vivo</i> detection of metabolic response: a pilot study of <sup>1</sup> H MR spectroscopy in extracranial lymphoma and germ cell tumours. <i>British Journal of Radiology</i> , 2002, 75, 959-966.	1.0	53
693	Cyclooxygenase Inhibition in Cancer – A Blind Alley or a New Therapeutic Reality?. <i>New England Journal of Medicine</i> , 2002, 346, 1085-1087.	13.9	28
694	Advanced pancreatic cancer – 5 years on. <i>Annals of Oncology</i> , 2002, 13, 1165-1168.	0.6	8
695	Clinical determinants of survival in patients with 5-fluorouracil- based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. <i>Annals of Oncology</i> , 2002, 13, 308-317.	0.6	407
696	Chemotherapy in colorectal cancer: new options and new challenges. <i>British Medical Bulletin</i> , 2002, 64, 159-180.	2.7	34
697	Multicenter Randomized Phase III Trial Comparing Protracted Venous Infusion (PVI) Fluorouracil (5-FU) With PVI 5-FU Plus Mitomycin in Inoperable Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 3130-3136.	0.8	132
698	Raltitrexed: current clinical status and future directions. <i>Annals of Oncology</i> , 2002, 13, 513-522.	0.6	62
699	Gemcitabine and Its Combinations in the Treatment of Malignant Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2002, 3, 97-104.	2.1	18
700	Prospective Randomized Trial Comparing Mitomycin, Cisplatin, and Protracted Venous-Infusion Fluorouracil (PVI 5-FU) With Epirubicin, Cisplatin, and PVI 5-FU in Advanced Esophagogastric Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 1996-2004.	0.8	449
701	Adjuvant therapy in colon cancer: current status and future directions. <i>Cancer Treatment Reviews</i> , 2002, 28, 223-236.	3.4	48
702	Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331. <i>Clinical Cancer Research</i> , 2002, 8, 103-9.	3.2	24



#	ARTICLE	IF	CITATIONS
703	Kirsten ras mutations in patients with colorectal cancer: the "RASCAL II"™ study. <i>British Journal of Cancer</i> , 2001, 85, 692-696.	2.9	790
704	New options for outpatient chemotherapy " the role of oral fluoropyrimidines. <i>Cancer Treatment Reviews</i> , 2001, 27, 211-220.	3.4	27
705	Lung Cancer After Hodgkin's Disease: A Nested Case-Control Study of the Relation to Treatment. <i>Journal of Clinical Oncology</i> , 2001, 19, 1610-1618.	0.8	128
706	Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO. <i>Blood</i> , 2001, 97, 2991-2997.	0.6	33
707	An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2001, 115, 786-792.	1.2	58
708	Thymidine Phosphorylase (TP) Activation: Convenience Through Innovation. <i>Oncologist</i> , 2001, 6, 1-2.	1.9	8
709	Optimizing the Use of Irinotecan in Colorectal Cancer. <i>Oncologist</i> , 2001, 6, 17-23.	1.9	29
710	Use of first line bronchoalveolar lavage in the immunosuppressed oncology patient. <i>Bone Marrow Transplantation</i> , 2001, 27, 967-971.	1.3	49
711	Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. <i>British Journal of Cancer</i> , 2001, 85, 1258-1264.	2.9	25
712	Current therapy and future prospects in lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2001, 1, 29-41.	1.1	2
713	The changing face of chemotherapy in colorectal cancer. <i>British Journal of Cancer</i> , 2001, 84, 1-7.	2.9	29
714	The bioavailability of oral fludarabine phosphate is unaffected by food. <i>The Hematology Journal</i> , 2001, 2, 316-321.	2.0	26
715	Optimizing the Use of Irinotecan in Colorectal Cancer. <i>Oncologist</i> , 2001, 6, 17-23.	1.9	10
716	A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. <i>British Journal of Haematology</i> , 2000, 109, 81-88.	1.2	101
717	FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study. <i>British Journal of Cancer</i> , 2000, 83, 287-293.	2.9	111
718	Risk of Second Malignancy After Hodgkin's Disease in a Collaborative British Cohort: The Relation to Age at Treatment. <i>Journal of Clinical Oncology</i> , 2000, 18, 498-498.	0.8	436
719	ECF in Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 3874-3875.	0.8	6
720	European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma. <i>Journal of Clinical Oncology</i> , 2000, 18, 317-317.	0.8	448

#	ARTICLE	IF	CITATIONS
721	Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2000, 18, 1812-1823.	0.8	434
722	Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma. <i>British Journal of Cancer</i> , 2000, 83, 146-152.	2.9	22
723	Adjuvant chemotherapy. <i>Lancet</i> , The, 2000, 356, 1276.	6.3	1
724	Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. <i>Lancet</i> , The, 2000, 355, 1041-1047.	6.3	3,031
725	High-Dose Therapy and Autologous Stem-Cell Transplantation for Adult Patients With Hodgkin's Disease Who Do Not Enter Remission After Induction Chemotherapy: Results in 175 Patients Reported to the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 1999, 17, 3101-3109.	0.8	148
726	Adjuvant or Palliative Chemotherapy for Colorectal Cancer in Patients 70 Years or Older. <i>Journal of Clinical Oncology</i> , 1999, 17, 2412-2412.	0.8	256
727	Low frequency of germline E-cadherin mutations in familial and nonfamilial gastric cancer. <i>British Journal of Cancer</i> , 1999, 79, 1935-1937.	2.9	61
728	Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. <i>British Journal of Cancer</i> , 1999, 80, 269-272.	2.9	250
729	Magnetic resonance detects metabolic changes associated with chemotherapy-induced apoptosis. <i>British Journal of Cancer</i> , 1999, 80, 1035-1041.	2.9	50
730	Human Bcl-2 antisense therapy for lymphomas. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1999, 1489, 97-106.	2.4	54
731	Safety of raltitrexed. <i>Lancet</i> , The, 1999, 354, 1824-1825.	6.3	11
732	Colorectal cancer. <i>Lancet</i> , The, 1999, 353, 1012-1013.	6.3	1
733	Optimum doses of irinotecan. <i>Lancet</i> , The, 1999, 353, 1276.	6.3	0
734	Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies. <i>Anti-Cancer Drugs</i> , 1999, 10, S5-S12.	0.7	8
735	Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma. <i>British Journal of Cancer</i> , 1999, 79, 1800-1805.	2.9	60
736	High-dose chemotherapy and autologous transplantation in lymphomatous polyposis in second remission: three case reports and literature review. <i>Bone Marrow Transplantation</i> , 1998, 22, 103-106.	1.3	0
737	The importance of CD34+/CD33 <sup>-</sup> cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue. <i>Bone Marrow Transplantation</i> , 1998, 22, 469-475.	1.3	29
738	Chemotherapy of oesophago-gastric cancer. <i>Pathology and Oncology Research</i> , 1998, 4, 87-95.	0.9	7

#	ARTICLE	IF	CITATIONS
739	A selective policy in follow-up for bowel cancer. <i>Lancet, The</i> , 1998, 351, 1891-1892.	6.3	0
740	Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. <i>Lancet, The</i> , 1998, 352, 1413-1418.	6.3	1,195
741	A Prognostic Score for Advanced Hodgkin's Disease. <i>New England Journal of Medicine</i> , 1998, 339, 1506-1514.	13.9	1,553
742	The importance of stabilization as an endpoint in the treatment of metastatic colorectal carcinoma: recent quality of life studies. <i>Anti-Cancer Drugs</i> , 1998, 9, 783-790.	0.7	10
743	Evaluation of Clinical Efficacy of New Medical Treatments in Advanced Colorectal Cancer. Results of a Workshop Organized by the Eortc Gitccg. <i>Tumori</i> , 1998, 84, 335-347.	0.6	14
744	Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.. <i>Journal of Clinical Oncology</i> , 1997, 15, 261-267.	0.8	835
745	New Approaches to the Treatment of Gastro-Intestinal Cancer. <i>Digestion</i> , 1997, 58, 508-519.	1.2	16
746	Inhibition of in vitro proliferation of Epstein Barr Virus infected B cells by an antisense oligodeoxynucleotide targeted against EBV latent membrane protein LMP1. <i>Oncogene</i> , 1997, 15, 489-493.	2.6	13
747	Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment. <i>Bone Marrow Transplantation</i> , 1997, 20, 435-443.	1.3	58
748	A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (Câ€VAMP) as induction treatment followed by autografting in previously untreated myeloma. <i>British Journal of Haematology</i> , 1997, 97, 153-160.	1.2	58
749	Comparison of Interferon Tolerance after Autologous Bone Marrow or Peripheral Blood Stem Cell Transplants for Myeloma Patients who have Responded to Induction Therapy. <i>Leukemia and Lymphoma</i> , 1996, 21, 421-427.	0.6	10
750	Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil.. <i>Journal of Clinical Oncology</i> , 1996, 14, 700-708.	0.8	294
751	Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. <i>Colorectal Cancer Working Party of the United Kingdom Medical Research Council</i> .. <i>Journal of Clinical Oncology</i> , 1996, 14, 2280-2288.	0.8	76
752	High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease - a pragmatic prognostic index. <i>British Journal of Cancer</i> , 1996, 73, 1272-1277.	2.9	19
753	CT evaluation of the resectability of gastric cancer postchemotherapy. <i>Abdominal Imaging</i> , 1996, 21, 293-298.	2.0	9
754	Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: Response, toxicity, quality of life, and survival. , 1996, 77, 1978-1985.		73
755	Curing gastric cancer-hone the scalpel with magic?. <i>British Journal of Cancer</i> , 1996, 73, 418-419.	2.9	4
756	Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 1995, 13, 2317-2323.	0.8	78

#	ARTICLE	IF	CITATIONS
757	Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer.. Journal of Clinical Oncology, 1995, 13, 1297-1302.	0.8	89
758	Evaluation of the efficacy of the VEEP regimen in adult Hodgkin's disease with assessment of gonadal and cardiac toxicity.. Journal of Clinical Oncology, 1995, 13, 387-395.	0.8	45
759	Survival after systemic therapy for metastatic colorectal cancer. Lancet, The, 1995, 345, 328-329.	6.3	4
760	High-dose melphalan for multiple myeloma: long-term follow-up data.. Journal of Clinical Oncology, 1994, 12, 764-768.	0.8	89
761	High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma.. Journal of Clinical Oncology, 1994, 12, 759-763.	0.8	199
762	Fludarabine in Lymphoproliferative Disorders: The Royal Marsden Hospital Experience. Leukemia and Lymphoma, 1994, 14, 17-23.	0.6	17
763	Application of scanning force microscopy to chromosome analysis. Cancer Genetics and Cytogenetics, 1994, 76, 93-95.	1.0	18
764	Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation. Lancet, The, 1994, 343, 696-700.	6.3	173
765	Meningeal carcinomatosis from transitional cell carcinoma of the bladder. Cancer, 1993, 72, 553-557.	2.0	30
766	Chemotherapy of carcinoma of the stomach. Cancer Treatment Reviews, 1993, 19, 29-44.	3.4	61
767	Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma.. Journal of Clinical Oncology, 1993, 11, 2273-2278.	0.8	83
768	Multiple myeloma: appearance at MR imaging.. Radiology, 1992, 182, 833-837.	3.6	121
769	Results of a Double Blind Placebo Controlled Study of Ondansetron as an Antiemetic During Total Body Irradiation in Patients Undergoing Bone Marrow Transplantation. Leukemia and Lymphoma, 1992, 7, 317-321.	0.6	33
770	Gut protection by cyclophosphamide ?priming? in patients receiving high-dose melphalan ? effect of drug scheduling. Cancer Chemotherapy and Pharmacology, 1992, 30, 149-151.	1.1	3
771	Alfacalcidol is a nontoxic, effective treatment of follicular small-cleaved cell lymphoma. British Journal of Cancer, 1991, 63, 463-465.	2.9	34
772	Dexamethasone can potentiate the anti-emetic action of a 5HT3 receptor antagonist on cyclophosphamide induced vomiting in the ferret. British Journal of Cancer, 1990, 61, 56-60.	2.9	45
773	Gastrointestinal non-Hodgkin's lymphoma. Bailliere's Clinical Gastroenterology, 1990, 4, 191-200.	0.9	1
774	DETECTING t(14;18) IN PARAFFIN-EMBEDDED LYMPHOMA TISSUE. Lancet, The, 1989, 333, 1131-1132.	6.3	4

#	ARTICLE	IF	CITATIONS
775	DETECTING t(14;18) IN PARAFFIN-EMBEDDED LYMPHOMA TISSUE. <i>Lancet, The</i> , 1989, 334, 218-219.	6.3	2
776	4-Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer. <i>Steroids</i> , 1987, 50, 245-252.	0.8	47
777	Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1987, 20, 253-255.	1.1	47
778	Marked inter-patient variation in adriamycin biotransformation to 7-deoxyaglycones: Evidence from metabolites identified in serum. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1986, 22, 991-1001.	0.9	32
779	Influence of polysorbate 80 (Tween 80) and etoposide (VP-16-213) on the pharmacokinetics and urinary excretion of adriamycin and its metabolites in cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1986, 17, 80-84.	1.1	21
780	Small cell lung cancer: Results of a phase II study of 1,2,4 triglycidylurazol. <i>Cancer Chemotherapy and Pharmacology</i> , 1986, 17, 85-86.	1.1	7
781	Comparison of serum and cerebrospinal fluid levels of methotrexate in man during high-dose chemotherapy for aggressive non-Hodgkin's lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1985, 15, 290-4.	1.1	13
782	High-dose cyclophosphamide and VP 16 as late dosage intensification therapy for small cell carcinoma of lung. <i>Cancer Chemotherapy and Pharmacology</i> , 1985, 15, 303-6.	1.1	25
783	A randomised multicentre single blind comparison of a cannabinoid anti-emetic (Levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1983, 19, 1087-1090.	0.9	23
784	Emerging treatments for advanced pancreatic cancer: clinical potential of albumin-bound paclitaxel. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 0, , 89.	5.5	0
785	Intravascular large B-cell lymphoma treated with polatuzumab-based salvage therapy: A rare case. <i>EJHaem</i> , 0, , .	0.4	0
786	[18F]Fluoromethylcholine PET/CT for CNS lymphoma assessment: a new tool. <i>F1000Research</i> , 0, 10, 1137.	0.8	0
787	Palliative Chemotherapy for Advanced Pancreatic Cancer. , 0, , 749-756.		0